

Appl. No.: 10/782,570

Amdt. Dated May 12, 2006

Reply to Office action of February 14, 2006

Amendments to the Drawings:

The drawings were objected to for legibility of the letters in darkened boxes the figures. Applicants have submitted herewith, replacement Figures 1A-1E in which the darkened boxes have been removed to improve legibility and clarity. Accordingly, the objection to the drawings should be withdrawn.

## REMARKS

### Status of the Claims

Claims 1-23 were rejected. Claims 12-18, 20 and 21 have been canceled without prejudice or disclaimer. Applicant reserves the right to pursue subject matter of claims 12-18, 20 and 21 in a continuation or divisional application. Claims 1-11, 19, and 22-23 are pending.

Claims 1, 2, 3, 11, 19, 22, and 23 have been amended. To expedite prosecution, claim 1 has been amended without prejudice or disclaimer to delete the subject matter drawn to a complement of the nucleic acid sequences of (a) through (d). Applicant reserves the right to pursue deleted subject matter of claim 1 in a continuation or divisional application. Claims 2, 3, 11, 19, 22 and 23 have been amended to more clearly define the scope of the invention. No new matter has been entered by way of these amendments.

### The Objection to the Claims Should Be Withdrawn

The Examiner has objected to Claim 11 for improper article usage. Claim 11 has been amended to recite "*the* plant" and is, therefore, in proper format. Claim 2 was objected to for failing to limit the subject matter of a previous claim from which it depends. Claim 2 has been amended to recite "*the* isolated" and, as such, properly limits the scope of claim 2. Accordingly, it is respectfully requested that the objection to claims 2 and 11 be withdrawn.

### The Rejections Under 35 U.S.C. § 112, First Paragraph, Should be Withdrawn

#### *Enablement*

The Examiner rejected claims 1-11, 19 and 22-23 under 35 U.S.C. § 112, first paragraph, on the grounds that the specification does not enable one skilled in the art to make or use the invention. This rejection is respectfully traversed.

The Examiner asserts that the specification, while enabling for nucleic acids encoding SEQ ID NO:2 or 4, host cells, plants, plant cells and seeds comprising them, and method of using them to make SEQ ID NO:2 or 4, does not reasonably provide enablement for methods and compositions drawn to nucleic acids encoding pesticidal protein with 95% sequence identity to SEQ ID NO:2 or 4, nucleic acids with 95% identity to SEQ ID NO:1 or 3, or a complement of

those nucleic acids, host cells, plants, plant cells and seeds comprising them, and method of using them to make a pesticidal protein with 95% identity to SEQ ID NO:1 or 3. The Examiner states that the specification fails to provide guidance for which amino acids of SEQ ID NO:2 or 4 can be altered and to which other amino acids, and which amino acids must not be changed, to maintain the activity of the encoded protein, as well as which regions of the protein can tolerate insertions and still produce a functional protein.

The Examiner appears to be suggesting that in order to satisfy the enablement requirement Applicants must demonstrate that every pesticidal polypeptide and variant and fragment thereof encompassed by the claims could be used to successfully practice the invention, such that no experimentation would be required. According to the applicable case law, however, the test of enablement is not whether experimentation is necessary to make and use an invention, but rather if experimentation is necessary, whether it is undue. *In re Angstadt*, 198 USPQ 214, 219 (C.C.P.A. 1976). Furthermore, a considerable amount of experimentation is permissible if it is merely routine or if the specification provides a reasonable amount of guidance in which the experimentation should proceed. *In re Wands*, 8 USPQ2d 1400 (Fed. Cir. 1988).

The test of whether an invention requires undue experimentation is not based on a single factor, but rather is a conclusion reached by weighing many factors. *Id.* at 1404. Factors to be considered in determining whether undue experimentation is required include the quantity of experimentation necessary, the amount of guidance provided in the specification, the presence of working examples of the invention in the application, the nature of the invention, the state of the prior art, the relative skill of those in the art, the predictability in the art, and the breadth of the claimed invention. *Id.* Accordingly, the holding of *Wands* does not require that Applicants provide as working examples every pesticidal polypeptide that could be used to practice the present invention. Rather, *Wands* sets out factors to be considered in determining whether undue experimentation is required to make and use the invention.

The Examiner argues that the specification does not enable one of skill in the art to make and use nucleic acids that encode polypeptides that retain pesticidal activity and have at least 95% sequence identity to SEQ ID NO:1 or 3, or 95% sequence identity to a nucleotide sequence that encodes SEQ ID NO:2 or 4. The Examiner incorrectly bases this conclusion solely on the

number of possible nucleic acids having the recited percent identity to SEQ ID NO:1 or 3, or a nucleotide sequence encoding SEQ ID NO:2 or 4 while ignoring the other factors set forth in *Wands* for assessing whether undue experimentation is required. In particular, the Examiner has improperly discounted the guidance provided in the specification and the working examples set forth in the application (page 4 of the Office Action mailed February 14, 2006).

First, sufficient guidance for making and using the recited sequences is present in the specification. The claimed variants and fragments of SEQ ID NO:1 or 3, or nucleotide sequences encoding SEQ ID NO:2 or 4 are limited by a percent identity (i.e., 95% identity) and further limited by the functional requirement that they possess pesticidal activity. Guidance for preparing variants and fragments of SEQ ID NO:1 or 3, or nucleotide sequences encoding SEQ ID NO:2 or 4 and for determining percent identity is provided in the specification and generally known in the art. See page 8, lines 20-29, and pages 9-13. Numerous delta-endotoxins were also well known in the art at the time the application was filed. See Crickmore *et al.* (1998) *Microbiol. Molec. Biol. Rev.* 62:807-813, which is incorporated by reference on page 2, lines 7-8 and is submitted herewith as Appendix A, and Crickmore *et al.* (2004) *Bacillus thuringiensis Toxin Nomenclature* at [lifesci.sussex.ac.uk/Home/Neil\\_Crickmore/Bt](http://lifesci.sussex.ac.uk/Home/Neil_Crickmore/Bt). The necessary molecular biology and mutagenesis techniques for preparing the variants and fragments of pesticidal sequences of the invention are routine. Moreover, methods for assessing the pesticidal activity of a polypeptide are readily available in the art and provided in the specification. See, for example, page 8, lines 25-29 and Examples 8 and 10.

In order to identify the pesticidal sequences encompassed by the present claims, one of skill in the art would only need to prepare variants and fragments of the nucleotide sequence of SEQ ID NO:1 or 3, or a nucleotide sequence encoding SEQ ID NO:2 or 4, having the specified characteristics recited in the claims (e.g., at least 95% identity) and then assay these polypeptides for pesticidal activity. Routine methods for preparing variants and fragments and testing the resulting polypeptides for pesticidal activity are routine in the art and described in the specification. Although some experimentation is required to practice the claimed invention, it is now customary in the art to generate a large number of sequences and to test them in a large-scale assay for a desired function, and, therefore, such experimentation is not undue, particularly

in view of the routine nature of the required methods. Contrary to the Examiner's conclusions, in order to identify variants and fragments of the nucleotide sequence of SEQ ID NO:1 or 3, or a nucleotide sequence encoding SEQ ID NO:2 or 4 that could be used in the invention, a person skilled in the art would only need to utilize standard molecular biology and mutagenesis techniques and routine screening tests for pesticidal activity. Therefore, given the level of skill and knowledge in the art, the availability of standard methods and assays, and the significant guidance provided in the specification, Applicants respectfully submit that the amount of experimentation required to identify delta-endotoxins and variants and fragments thereof having pesticidal activity and the structural features recited in the claims is routine, not undue.

The Examiner further argues that mutation of sequences, even conservative substitutions, does not produce predictable results and, therefore, the specification is not enabling with respect to variants of the nucleotide sequence of SEQ ID NO:1 or 3, or a nucleotide sequence encoding SEQ ID NO:2 or 4. The Office Action cites Lazar *et al.* (1988) *Molecular and Cellular Biology* 8:1247-1252 and Hill *et al.* (1998) *Biochem. Biophys. Res. Comm.* 244:573-577 in support of the general unpredictability of the art with respect to modification of nucleotide sequences. Each reference, however, simply teaches that alteration of highly conserved sequences will disrupt function. Lazar *et al.* teach that alterations in amino acid residues 47 and 48 in TGF-alpha can alter the activity of the polypeptide. Contrary to the Examiner's conclusion, the alteration in the polypeptide was specifically designed to occur at amino acid positions that are highly conserved in the EGF-like family of polypeptides. Similarly, the modified residues described by Hill *et al.* were conserved among bacterial and plant ADP-glucose pyrophosphorylases. As set forth in the first line of the abstract, "[t]wo *absolutely conserved* histidines and a third *highly conserved* histidine are noted in eleven bacterial and plant ADP-glucose pyrophosphorylases" (emphasis added). These absolutely and highly conserved histidines were mutagenized and characterized in the paper. One of skill in the art would not be surprised that modification of one of these highly conserved amino acids would lead to the loss of function described by the authors. Applicants further note that the Lazar *et al.* and the Hill *et al.* references are directed to TGF-alpha and ADP-glucose pyrophosphorylase, neither of which has any relation to the pesticidal sequences of the present invention. Thus, the cited references do not support the Examiner's broad assertion

of inherent unpredictability of protein function resulting from the mutation of the underlying nucleotide sequence. In fact, both references support Applicants' arguments that at the time the application was filed one of skill in the art could modify polypeptide sequences and test the resulting variants for biological activity.

Furthermore, the specification provides guidance regarding conservative modifications that are unlikely to disrupt biological activity. See, for example, pages 11-12. Thus, by reference to a standard codon table, one of skill in the art could predict which modifications would not affect the biological activity of the encoded polypeptide. Also, the specification highlights conserved residues that are not likely to tolerate substitution (see Figures 1 and 2 as originally filed) and delineates conserved domains characteristic of delta-endotoxin proteins (see page 4, lines 5-11). The replacement figures do not highlight conserved residues, however, one of skill in the art would understand how to use the alignment provided in the replacement figure to identify conserved residues using, for example, the methods described in the instant specification (see pages 10-11).

Moreover, as described above, Applicants have disclosed pesticidal sequences, and variants and fragments thereof, and the art was replete with additional delta-endotoxin sequences at the time the application was filed. Information relating to conserved regions of delta-endotoxins may be obtained from these sequences. A person of skill in the art would appreciate that comparison and alignment of known delta-endotoxin sequences may reveal information regarding appropriate sites or regions for modifications. By aligning these sequences, one may be able to identify conserved residues or regions within these proteins that are unlikely to tolerate mutation and still retain pesticidal activity. Methods for aligning sequences, such as by using the CLUSTAL algorithm, are described in the specification. See pages 10-11.

In addition, detailed information about the structure of delta-endotoxins was known in the art. See, for example, Li *et al.* (1991) *Nature* 353:815-821 (describing the crystal structure of the Cry3A protein), which is incorporated by reference on page 12 of the specification, and Morse *et al.* (2001) *Structure* 9:409-417, both of which are submitted herewith (Appendices B and C, respectively). Delta-endotoxins are extremely well-characterized and related to each other to various degrees by similarities in their amino acid sequences and tertiary structures. A combined

consideration of the published structural analyses of delta-endotoxins and the reported functions associated with particular structures, motifs, and the like indicates that specific regions of the toxin are correlated with particular functions and discrete steps of the mode of action of the protein. Thus, a rational scheme for determining the regions of a delta-endotoxin that would tolerate modification is provided. Based on the regions of delta-endotoxins that are conserved among protein family members, the skilled artisan could choose among possible modifications to produce polypeptides within the structural parameters set forth in the claims and then test these modified variants to determine if they retain pesticidal activity. In light of the guidance provided in the specification and the state of the art with respect to delta-endotoxins, a skilled artisan could readily conclude which amino acids are essential for structure and function and could envisage similar sequences that are 95% identical to the nucleotide sequence of SEQ ID NO:1 or 3, or a nucleotide sequence encoding SEQ ID NO:2 or 4, and that retain pesticidal activity. As such, one of skill in the art could identify the pesticidal sequences encompassed by the present claims without undue experimentation.

The Examiner has also cited Guo *et al.* (2004) *Proc. Natl. Acad. Sci. USA* 101:9205-9210 for the proposition that increasing the number of amino acid substitutions in a protein increases the probability that the protein will be functionally inactivated. The Examiner uses this reference as evidence that making and analyzing delta-endotoxins that have multiple amino acid substitutions but that still retain pesticidal activity will require undue experimentation. The Examiner, however, has mischaracterized the Guo *et al.* reference. The cited reference is directed to analysis of the probability that a *random* amino acid replacement will lead to a protein's functional inactivation (emphasis added). In contrast, the specification provides a rational and systematic method for designing delta-endotoxin variants that retain pesticidal activity. One of skill in the art would appreciate that regions known to be important for pesticidal activity would be unlikely to tolerate significant mutation and, therefore, would not expect such mutations to result in a biologically active protein. Thus, the teachings of Guo *et al.* do not support the Examiner's conclusion that the present claims lack enablement.

The Examiner further relies on the teachings of de Maagd *et al.* (1999) *Appl. Environ. Microbiol.* 65:4369-4374, Tounsi *et al.* (2003) *J. Appl. Microbiol.* 95:23-28 and

Angsuthanasombat *et al.* (2001) *J. Biochem. Mol. Biol.* 34:402-407 in support of the assertion that amino acid substitutions in delta-endotoxin proteins are unpredictable. However, each of these references describes substitutions (which are largely non-conservative) in *conserved* regions. de Maagd *et al.* teaches that the insertion of several groups of amino acids within Domain III of Cry1E with the corresponding amino acids of Cry1C will alter the specificity and/or toxicity of Cry1E. Since the conserved Domain III is well known by those of skill in the art to be involved in specificity of a delta-endotoxin toward a pest, it would be no surprise that alteration of this domain could affect specificity of the protein. In fact, that was the intention of de Maagd *et al.* Similarly, Tounsi *et al.* discuss the single amino acid difference between Cry1Ia1 and Cry1Ia2 (which is a non-conservative substitution of aspartic acid for tyrosine at position 233) as being critical to insecticidal specificity of these two toxins. Again, this substitution occurs in the conserved Domain I. Finally, Angsuthanasombat *et al.* teach a critical amino acid residue at position 136 where even a conservative substitution could lead to loss of pesticidal activity. Yet again, the authors specifically targeted amino acids in conserved Domain I in order to alter function. Since the instant specification clearly defines the conserved domains described by the aforementioned references with respect to the claimed sequences (see page 4), one of skill in the art would appreciate that substitutions made in these domains could lead to a loss of specificity and/or toxicity. Further, the references cited by the Examiner actually support the Applicant's assertion that one of skill in the art at the time of the invention would understand which residues could be altered to *change* the function of delta-endotoxins, implying that one of skill would equally understand which residues *not* to change when maintenance of function is desired.

In establishing non-enablement, the burden rests initially with the Examiner to substantiate the unpredictability of the art and that, given the unpredictability, the specification does not provide sufficient information to guide those of skill to make and use the claimed invention across the full scope of the claims. In view of the discussion above, the references cited by the Examiner fails to support the position that claims 1-11, 19, and 22-25 are not enabled.



The Examiner also states that the specification fails to teach how to use a complement of nucleic acids encoding pesticidal protein with 95% identity to SEQ ID NO:2 or 4 or nucleic acids with 95% identity to SEQ ID NO:1 or 3. The Applicant respectfully disagrees. Page 8, lines 2-7 state that the complement of a claimed nucleotide sequence is one that would hybridize to a given nucleotide sequence to thereby form a stable duplex. Page 13, lines 24-25 state that hybridization methods (using, for example, complementary sequences) can be used to screen cDNA or genomic libraries for delta-endotoxin sequences having substantial identity to the sequences of the invention. Therefore, the specification clearly teaches how to use the complement of a nucleic acid sequence of the invention to, for example, screen for similar delta-endotoxin sequences. However, to expedite prosecution, claim 1 has been amended to delete the subject matter pertaining to complementary sequences.

The Examiner further maintains that the specification does not enable the transformation of any plant with a nucleotide sequence with 95% identity to the nucleotide sequence of SEQ ID NO:1 or 3, or a nucleotide sequence encoding SEQ ID NO:2 or 4 because undue trial and error experimentation would be required to screen for nucleotide sequences encompassed by the claims and plants transformed therewith to identify those plants with pesticidal activity. As discussed above, the amount of experimentation required to identify a nucleotide sequence that has 95% sequence identity to SEQ ID NO:1 or 3, or to a nucleotide sequence encoding SEQ ID NO:2 or 4 is not undue. With respect to transformation of plants with these sequences, the specification provides routine methods for transformation of plants with nucleotide sequences and the regeneration of transgenic plants. See pages 20-27 and Examples 12 and 13. Given the guidance provided in the specification and the knowledge in the art, the claims directed to transformation of a plant with a delta-endotoxin sequence, or variant or fragment thereof, are fully enabled.

In light of the above arguments, the level of skill and knowledge in the art, and the guidance provided in the specification, Applicants respectfully submit that the specification is enabling for the full scope of claims 1-11, 19, and 22-23. Thus, the rejection of the claims under 35 U.S.C. § 112, first paragraph, for lack of enablement should be withdrawn.

Written Description

Claims 1-11, 19, and 22-25 were further rejected under 35 U.S.C. § 112, first paragraph, as failing to satisfy the written description requirement. The rejection is respectfully traversed.

The Examiner asserts that the disclosure is insufficient to support claims that are drawn to a genus of nucleic acids having 95% sequence identity to SEQ ID NO:1 or 3, or nucleic acids encoding polypeptides having 95% identity to SEQ ID NO:2 or 4.

In order to satisfy the written description requirement of 35 U.S.C. § 112, the application must reasonably convey to one skilled in the art that the applicant was in possession of the claimed subject matter at the time the application was filed. *Vas-Cath Inc. v. Mahurkar*, 935 F.2d 1555, 1563, 19 U.S.P.Q.2d (BNA) 1111, 1117 (Fed. Cir. 1991). Every species encompassed by the claimed invention, however, need not be disclosed in the specification to satisfy the written description requirement of 35 U.S.C. § 112, first paragraph. *Utter v. Hiraga*, 845 F.2d 993, 6 USPQ2d 1709 (Fed. Cir. 1988). The Federal Circuit has made it clear that sufficient written description requires simply the knowledge and level of skill in the art to permit one of skill to immediately envision the product claimed from the disclosure. *Purdue Pharm L.P. v. Faulding In.*, 230 F.3d 1320 1323, 596 USPQ2d 1481, 1483 (Fed. Cir. 2000) (“One skilled in the art must immediately discern the limitations at issue in the claims.”).

Moreover, the “Guidelines for Examination of Patent Applications Under 35 U.S.C. §112, ¶ 1, 'Written Description' Requirement” state that a genus may be described by “sufficient description of a representative number of species . . . or by disclosure of relevant, identifying characteristics , *i.e.* structure or other physical and/or chemical properties.” *Id.* at 1106. This is in accordance with the standard for written description set forth in *Regents of the University of California v. Eli Lilly & Co*, 119 F.3d 1559 (Fed. Cir. 1997), where the court held that “[a] written description of an invention involving a chemical genus, like a description of a chemical species, ‘requires a precise definition, such as by structure, formula, or chemical name’ of the claimed subject matter sufficient to distinguish it from other materials.” 119 F.3d at 1568, citing *Fiers v. Revel* 984 F.2d 1164 (Fed. Cir. 1993). In *Enzo Biochem, Inc. v. Gen-Probe, Inc.*, 323 F.2d 926 (Fed. Cir. 2002), the Federal Circuit adopted the PTO standard for written description, stating:

[U]nder the Guidelines, the written description requirement would be met . . . if the functional characteristics of [a genus of polypeptides] were coupled with a disclosed correlation between that function and a structure that is sufficiently known or disclosed. We are persuaded by the Guidelines on this point and adopt the PTO's applicable standard for determining compliance with the written description requirement.”

The claims of the present application meet the requirements for written description set forth by the Federal Circuit. The claims recite that the nucleic acid have 95% sequence identity to the nucleotide sequence of SEQ ID NO:1 or 3, or to a nucleotide sequence encoding SEQ ID NO:2 or 4. Methods for determining percent identity between any two sequences are known in the art and are provided in the specification. See pages 9-11. As discussed above, nucleotide sequences for full-length AXMI-007 (SEQ ID NO:1), as well as variants and fragments (e.g., SEQ ID NO:3) are disclosed in the specification. Numerous delta-endotoxin sequences were also generally known in the art at the time the application was filed. Moreover, detailed information regarding the structure of delta-endotoxins and the reported functions associated with particular structures, regions, and motifs was also available in the prior art as well as discussed in detail on page 2, lines 21-28, Figure legend 1, and on page 12. At the time of filing, it was known that delta-endotoxins generally comprise three domains, a seven-helix bundle that is involved in pore formation, a three-sheet domain that has been implicated in pore formation, and a beta-sandwich motif. See Li *et al.* (1991) *Nature* 305:815-821. Thus, the recitation of polypeptides having a particular percent identity to a delta-endotoxin provides very specific and defined structural parameters of the sequences that can be used in the invention. These structural limitations are sufficient to distinguish the nucleotide and amino acid sequences of the invention from other nucleic acids and polypeptides and thus sufficiently define the genus of sequences useful in the practice of the present invention.

The Examiner is reminded that the description of a representative number of species does not require the description to be of such specificity that it would provide individual support for each species that the genus embraces. 66 Fed. Reg. 1099, 1106 (2000). Satisfactory disclosure of a “representative number” depends on whether one of skill in the art would recognize that the applicant was in possession of the necessary common attributes or features of the elements

possessed by the members of the genus in view of the species disclosed. 66 Fed. Reg. 1099, 1106 (2000). Here, Applicants have provided nucleotide and amino acid sequences for exemplary pesticidal sequences and variants and fragments thereof encompassed by the claims. Moreover, numerous delta-endotoxin sequences were known and readily available in the art. Therefore, Applicants submit that in view of the present disclosure and the knowledge and level of skill in the art the skilled artisan would envision the claimed invention.

The description of a claimed genus can be by structure, formula, chemical name, or physical properties. *See Ex parte Maizel*, 27 USPQ2d 1662, 1669 (B.P.A.I. 1992), *citing Amgen v. Chugai*, 927 F.2d 1200, 1206 (Fed. Cir. 1991). A genus of polypeptides may therefore be described by means of a recitation of a representative number of amino acid sequences that fall within the scope of the genus, *or* by means of a recitation of structural features common to the genus, which features constitute a substantial portion of the genus. *See Regents of the University of California v. Eli Lilly & Co.*, 119 F.3d 1559, 1569 (Fed. Cir. 1997); *see also* Guidelines for Examination of Patent Applications Under the 35 U.S.C. 112, first paragraph, "Written Description" Requirement, 66 Fed. Reg. 1099, 1106 (2000). The recitation of a predictable structure (i.e., an amino acid sequence having a specified percent identity or number of contiguous amino acid residues of a particular sequence) is sufficient to satisfy the written description requirement. Thus, the application provides the structural features that characterize sequences having at least 95% sequence identity to SEQ ID NO:1 or 3, or to a nucleotide sequence encoding SEQ ID NO:2 or 4 that retain pesticidal activity.

An Applicant may also rely upon functional characteristics in the description, provided there is a correlation between the function and structure of the sequences recited in the claims. *Id.*, *citing Lilly* at 1568. The present claims further recite functional characteristics that distinguish the sequences of the claimed genus. Specifically, the claims recite that the sequences having at least 95% sequence identity to SEQ ID NO:1 or 3, or to a nucleotide sequence encoding SEQ ID NO:2 or 4 encode proteins which have pesticidal activity. The specification and the art provide standard assays that may be used to measure pesticidal activity. *See*, for example, page 11, lines 20-24. Furthermore, as noted above, Applicants have disclosed fragment sequences that retain pesticidal activity (e.g., SEQ ID NO:3, which encodes a fragment of SEQ

ID NO:2). Accordingly, both the structural and functional properties that characterize the genus of sequences that can be used to practice the invention are specifically recited in the claims. The sequences that fall within the scope of the claims can readily be identified by the methods set forth in the specification.

In summary, the specification provides an adequate written description of the claimed invention. In particular, the specification provides: nucleotide and amino acid sequences for pesticidal toxins, and variants and fragments thereof, that fall within the scope of the claims; guidance regarding sequence alterations that do not disrupt pesticidal activity of a toxin; guidance for determining percent identity; and methods for assaying the pesticidal activity of proteins. In view of the above remarks and claim amendments, Applicants submit that the relevant identifying structural and functional properties of the genus of sequences of the present invention would be clearly recognized by one of skill in the art. Consequently, Applicants were in possession of the invention at the time the application was filed, and the rejection of the claims under 35 U.S.C. § 112, first paragraph, for lack of written description should be withdrawn.

The Rejection of the Claims Under 35 U.S.C. § 112, Second Paragraph Should Be Withdrawn

Claims 3, 11, and 19, as well as dependent claims therefrom, were rejected under 35 U.S.C. § 112, second paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter that Applicant regards as the invention.

Claim 3 has been amended to recite “relative to the GC content of SEQ ID NO:1 or 3.” Support for this amendment can be found on page 25, lines 2-3. Claim 11 has been amended to recite “*the* plant” of claim 9. Claim 9 depends from claim 8, which depends from claim 6, which depends from claim 4, which depends from claim 1. Therefore, as amended, claim 11 now describes a transgenic seed derived from a plant that comprises a host cell that contains a vector comprising the nucleic acid of claim 1. Claim 19 has been amended to recite “*the* nucleic acid molecule” such that claim 19 now encompasses a method for producing a polypeptide by culturing a host cell that contains a vector that comprises the nucleic acid of claim 1.

Appl. No.: 10/782,570  
Amdt. Dated May 12, 2006  
Reply to Office action of February 14, 2006


Accordingly, the rejection of claims 3, 11, and 19 under 35 U.S.C. § 112, second paragraph should be withdrawn.

The Rejection of the Claims Under 35 U.S.C. § 102 Should Be Withdrawn

Claims 22 and 23 were rejected under 35 U.S.C. § 102(b) as being anticipated by Barton *et al.* (U.S. Patent No. 6,833,449). Barton *et al.* teach tobacco plants transformed with a nucleic acid encoding a CryI protein. The Examiner states that the recitation of “a” before “nucleotide sequence of SEQ ID NO:1 or 3” in parts (a) and (d) and “an” before “amino acid sequence of SEQ ID NO:2 or 4” in part (c) encompasses nucleic acids that comprise the full-length sequence of SEQ ID NO:1 or 3, or any portion of SEQ ID NO:1 or 3 or that encode the full-length of SEQ ID NO:2 or 4 or any portion of SEQ ID NO:2 or 4. Claims 22 and 23 have been amended to recite “the” before “nucleotide sequence” and “amino acid sequence.” As such, the CryI protein taught in Barton *et al.* does not comprise the sequence of SEQ ID NO:1 or 3, nor a sequence with 95% identity to SEQ ID NO:1 or 3. Accordingly, the rejection of claims 22 and 23 under 35 U.S.C. § 102(b) should be withdrawn.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those that may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,




W. Murray Spruill  
Registration No. 32,943

Appl. No.: 10/782,570  
Amdt. Dated May 12, 2006  
Reply to Office action of February 14, 2006

"Express Mail" mailing label number EV395779905US  
Date of Deposit May 12, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:  
Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

  
Nora C. Martinez

## Revision of the Nomenclature for the *Bacillus thuringiensis* Pesticidal Crystal Proteins

N. CRICKMORE,<sup>1</sup> D. R. ZEIGLER,<sup>2</sup> J. FEITELSON,<sup>3</sup> E. SCHNEPF,<sup>3</sup> J. VAN RIE,<sup>4</sup>  
 D. LERECLUS,<sup>5</sup> J. BAUM,<sup>6</sup> AND D. H. DEAN<sup>2\*</sup>

*School of Biological Sciences, University of Sussex, Brighton, United Kingdom<sup>1</sup>; Department of Biochemistry, The Ohio State University, Columbus, Ohio 43210<sup>2</sup>; Mycogen Corp., San Diego California 92121<sup>3</sup>; Plant Genetic Systems, n. v., Ghent, Belgium<sup>4</sup>; Unité de Biochimie Microbienne, Institut Pasteur, Paris, France<sup>5</sup>; and Ecogen, Inc., Langhorne, Pennsylvania 19047<sup>6</sup>*

BACKGROUND AND HISTORY OF PESTICIDAL CRYSTAL PROTEIN NOMENCLATURE .....	807
PROPOSED NOMENCLATURE .....	807
ROBUSTNESS OF THE NOMENCLATURE .....	808
ACKNOWLEDGMENTS .....	811
REFERENCES .....	811

### BACKGROUND AND HISTORY OF PESTICIDAL CRYSTAL PROTEIN NOMENCLATURE

Since the first cloning of an insecticidal crystal protein gene from *Bacillus thuringiensis* (91), many other such genes have been isolated. Initially, each newly characterized gene or protein received an arbitrary designation from its discoverers: *icp* (64); *cry* (21, 121); *kurhd1* (31); Bta (88); bt1, bt2, etc. (40); type B and type C (43); and 4.5 kb, 5.3 kb, and 6.6 kb (55). The first systematic attempt to organize the genetic nomenclature relied on the insecticidal activities of crystal proteins for the primary ranking of their corresponding genes (44). The *cryI* genes encoded proteins toxic to lepidopterans; *cryII* genes encoded proteins toxic to both lepidopterans and dipterans; *cryIII* genes encoded proteins toxic to coleopterans; and *cryIV* genes encoded proteins toxic to dipterans alone.

This system provided a useful framework for classifying the ever-expanding set of known genes. Inconsistencies existed in the original scheme, however, due to attempts to accommodate genes that were highly homologous to known genes but did not encode a toxin with a similar insecticidal spectrum. The *cryIIB* gene, for example, received a place in the lepidopteran-dipteran class with *cryIIA*, even though toxicity against dipterans could not be demonstrated for the toxin designated CryIIB. Other anomalies arose after the nomenclature was established. The protein named CryIC, for example, was reported to be toxic to both dipterans and lepidopterans (103), while the protein designated CryIB was reported to be toxic to both lepidopterans and coleopterans (8). Because the nomenclature system provided no central committee or database to maintain standardization, new genes encoding a diverse set of proteins without a common insecticidal activity each received the name *cryV*, based on the next available Roman numeral (32, 46, 67, 100, 102, 108).

### PROPOSED NOMENCLATURE

We propose in this review a revised nomenclature for the *cry* and *cyt* genes. To organize the wealth of data produced by genomic sequencing efforts, a new nomenclatural paradigm is emerging, exemplified by the internationally recognized cyto-

chrome P-450 superfamily nomenclature system (68a, 122a). Our proposal conforms closely to this model both in conceptual basis and in nomenclature format. The underlying basis of this type of system is to assign names to members of gene superfamilies according to their degree of evolutionary divergence as estimated by phylogenetic tree algorithms. The nomenclature format in such a system is designed to convey rich informational content about these relationships by appending to the mnemonic root a series of numerals and letters assigned in a hierarchical fashion to indicate degrees of phylogenetic divergence. This change from a function-based to a sequence-based nomenclature allows closely related toxins to be ranked together and removes the necessity for researchers to bioassay each new protein against a growing series of organisms before assigning it a name.

In our proposed revision, Roman numerals have been exchanged for Arabic numerals in the primary rank (e.g., Cry1Aa) to better accommodate the large number of expected new proteins. The mnemonic Cyt to designate crystal proteins showing a general cytolytic activity in vitro has been retained because of its historical precedent and entrenchment in the research literature. Our definition of a Cry protein is rather broad: a parasporal inclusion (crystal) protein from *B. thuringiensis* that exhibits some experimentally verifiable toxic effect to a target organism, or any protein that has obvious sequence similarity to a known Cry protein. Similarly, Cyt denotes a parasporal inclusion (crystal) protein from *B. thuringiensis* that exhibits hemolytic activity, or any protein that has obvious sequence similarity to a known Cyt protein. By these criteria, the nontoxic 40-kDa crystal protein from *B. thuringiensis* subsp. *thompsoni*, for example, has been excluded from our list, but the lepidopteran-active 34-kDa protein (now Cry15A) encoded by an adjacent gene has been included (11).

The freely available software applications CLUSTAL W (110) and PHYLIP (27) define the sequence relationships among the toxins to form the framework of the new nomenclature. In the first step, CLUSTAL W aligns the deduced amino acid sequences of the full-length toxins and produces a distance matrix, quantitating the sequence similarities among the set of toxins. CLUSTAL W default settings are employed, except that the "delay divergent sequences" setting in the multiple-alignment parameter menu is reduced from 40 to 0%. The NEIGHBOR application within the PHYLIP package then constructs a phylogenetic tree from the distance matrix by an unweighted pair-group method using arithmetic averages

\* Corresponding author. Mailing address: Department of Biochemistry, 484 West Twelfth Ave., Columbus, OH 43210. Phone: (614) 292-8829. Fax: (614) 292-6773. E-mail: dean.10@osu.edu.



(UPGMA) algorithm. The TREEVIEW application (73), with the "phylogenetic tree" and "ladderize left" options selected, produces a graphic presentation of the resulting tree.

We have applied this procedure to the set of holotype sequences given in Table 1 to produce the phylogenetic tree presented in Fig. 1. Vertical lines drawn through the tree show the boundaries used to define the various nomenclatural ranks. The name given to any particular toxin depends on the location of the node where the toxin enters the tree relative to these boundaries. A new toxin that joins the tree to the left of the leftmost boundary will be assigned a new primary rank (an Arabic number). A toxin that enters the tree between the left and central boundaries will be assigned a new secondary rank (an uppercase letter). It will have the same primary rank as the other toxins within that cluster. A toxin that enters the tree between the central and right boundaries will be assigned a new tertiary rank (a lowercase letter). Finally, a toxin that joins the tree to the right of the rightmost boundary will be assigned a new quaternary rank (another Arabic number). Toxins with identical sequences but isolated independently will receive separate quaternary ranks.

By this method each toxin will be assigned a unique name incorporating all four ranks. A completely novel toxin would currently be assigned the name Cry23Aa1. For the sake of convenience, however, we propose that the inclusion of the tertiary rank *a* and quaternary rank 1 be optional, their use dictated only by a need for clarity. This new toxin could therefore simply be referred to as Cry23A.

In choosing locations for rank boundaries, we attempted to construct a nomenclature reflecting significant evolutionary relationships while at the same time minimizing changes from the gene names assigned under the old system. In the resulting system, proteins with a common primary rank are similar enough that the percent identity can be defined with some confidence. Proteins with the same primary rank often affect the same order of insect; those with different secondary and tertiary ranks may have altered potency and targeting within an order. At the tertiary rank, differences can be due to the accumulation of dispersed point mutations, but often they appear to have resulted from ancestral recombination events between genes differing at a lower rank level (9). The quaternary rank was established to group "alleles" of genes coding for known toxins that differ only slightly, either because of a few mutational changes or an imprecision in sequencing. To avoid confusion, however, the reader should bear in mind the differences between the quaternary rank number and the classical concept of the allele. Any *cry* gene specified with a quaternary rank is a natural isolate. No assumption about functionality is implied by the presence of this rank number in the gene name. In contrast, an allele number would be assumed, unless parenthetical or subscripted information indicated otherwise, to denote a nonfunctional mutant form of a wild-type gene found at a discrete genetic locus. Because of the somewhat modular nature of the Cry proteins and the effect that various segmental relationships could have on the clustering algorithm, it is likely that these boundaries will move slightly or even bend as the addition of new sequences changes the topology of the phylogenetic tree. Currently the boundaries represent approximately 95, 78, and 45% sequence identity.

A *B. thuringiensis* Pesticidal Crystal Protein Nomenclature Committee, consisting of the authors of this paper, will remain as a standing committee of the *Bacillus* Genetic Stock Center (BGSC) to assist workers in the field of *B. thuringiensis* genetics in assigning names to new Cry and Cyt toxins. The corresponding gene or protein sequences must first be deposited into a publicly accessible database (GenBank, EMBL, or PIR) and

released by the repository for electronic publication in the database so that the scientific community may conduct an independent analysis. Researchers should submit new sequences directly to the BGSC director (D. R. Zeigler), either by electronic mail (zeigler.1@osu.edu) or on computer diskette. The director will analyze the amino acid sequence as described above and suggest the appropriate name, subject to the approval of the committee. The committee will periodically review the literature of the Cry and Cyt toxins and publish a comprehensive list. This list, alongside other relevant information, will also be available via the Internet at the following URL: [http://www.biols.susx.ac.uk/Home/Neil\\_Crickmore/Bt/](http://www.biols.susx.ac.uk/Home/Neil_Crickmore/Bt/).

The current list of *cry* and *cyt* genes (including quaternary ranks) is given in Table 1. New gene names are listed with their previous names, their GenBank accession numbers, and published references. The quaternary ranks were assigned in the order that the gene sequences were discovered in the literature or submitted to the committee. Genes assigned the quaternary rank 1 represent holotype sequences.

The boundaries shown in Fig. 1 allow most *cry* genes to retain the names they received under the system of Höfte and Whiteley (44), after a substitution of Arabic for Roman numerals. There are a few notable exceptions: *cryIG* becomes *cry9A*, *cryIIIC* becomes *cry7Aa*, *cryIIID* becomes *cry3C*, *cryIVC* becomes *cry10A*, *cryIVD* becomes *cry11A*, *cytA* becomes *cyt1A*, and *cytB* becomes *cyt2A* (Table 1). Under the revised system, the known Cry and Cyt proteins fall into 24 sets at the primary rank—Cyt1, Cyt2, and Cry1 through Cry22.

## ROBUSTNESS OF THE NOMENCLATURE

The robustness of the current naming process was assessed by a number of additional analyses. The choice of clustering algorithm (unweighted pair-group method using arithmetic averages) was driven largely by the consistent location of a root and constant branch lengths, resulting in a common vertical alignment of sequence names and essentially allowing a "ruler across the tree" approach to naming. It has the drawback of imposing a common evolutionary clock on the clustering process, an assumption that cannot be assured. The distance metric related to percent identity (essentially 1 minus the fraction of identical residues of the total compared without gaps) is the one most commonly found as the output of sequence comparison programs, including CLUSTAL W. For phylogenetic analysis, a more usual distance metric relates to the number of substitutions per site to convert one sequence to the other (e.g., Dayhoff's point accepted mutation [PAM]) and accounts for the possibility of multiple substitutions per site as the sequences are more divergent. The latter method has the drawback of being more computationally intensive, and, for very divergent sequences, requiring too large a value, resulting in numeric computation failures. They also differ in the way sequences of unequal length are handled, with the percent identity method typically ignoring excess sequence and the other methods assigning a penalty. This is particularly important for crystal proteins, since a number of them lack the C-terminal protoxin segments yet are quite related to some longer toxins in the N-terminal toxin segment; we feel that the stronger association of such relationships found by the percent identity method is preferred.

To assess the effect of using the neighbor-joining method to generate an unrooted tree, CLUSTAL W routines were used to generate such a tree with 1,000 bootstraps of the sequence alignment we used for Fig. 1. When an appropriate outgroup was chosen, the resulting tree (not shown) resembled our Fig. 1. The bootstrap values indicated that the tree thus generated

TABLE 1. Known *cry* and *cyt* gene sequences with revised nomenclature assignments

Revised gene name	Original gene or protein name	Accession no.	Coding region <sup>a</sup>	Reference	Revised gene name	Original gene or protein name	Accession no.	2125–3990>	Reference
<i>cry1Aa1</i>	<i>cryIA(a)</i>	M11250	527–4054	92	<i>cry2Ab2</i>	<i>cryIIB</i>	X55416	874–2775	17
<i>cry1Aa2</i>	<i>cryIA(a)</i>	M10917	153–>2955	98	<i>cry2Ac1</i>	<i>cryIIC</i>	X57252	2125–3990	124
<i>cry1Aa3</i>	<i>cryIA(a)</i>	D00348	73–3600	99	<i>cry3Aa1</i>	<i>cryIIIA</i>	M22472	25–1956	39
<i>cry1Aa4</i>	<i>cryIA(a)</i>	X13535	1–3528	62	<i>cry3Aa2</i>	<i>cryIIIA</i>	J02978	241–2172	93
<i>cry1Aa5</i>	<i>cryIA(a)</i>	D17518	81–3608	113	<i>cry3Aa3</i>	<i>cryIIIA</i>	Y00420	566–2497	41
<i>cry1Aa6</i>	<i>cryIA(a)</i>	U43605	1–>1860	63	<i>cry3Aa4</i>	<i>cryIIIA</i>	M30503	201–2132	65
<i>cry1Ab1</i>	<i>cryIA(b)</i>	M13898	142–3606	119	<i>cry3Aa5</i>	<i>cryIIIA</i>	M37207	569–2500	22
<i>cry1Ab2</i>	<i>cryIA(b)</i>	M12661	155–3622	111	<i>cry3Aa6</i>	<i>cryIIIA</i>	U10985	569–2500	1
<i>cry1Ab3</i>	<i>cryIA(b)</i>	M15271	156–3620	31	<i>cry3Ba1</i>	<i>cryIIIB2</i>	X17123	25–>1977	101
<i>cry1Ab4</i>	<i>cryIA(b)</i>	D00117	163–3627	50	<i>cry3Ba2</i>	<i>cryIIIB</i>	A07234	342–2297	85
<i>cry1Ab5</i>	<i>cryIA(b)</i>	X04698	141–3605	40	<i>cry3Bb1</i>	<i>cryIIIBb</i>	M89794	202–2157	24
<i>cry1Ab6</i>	<i>cryIA(b)</i>	M37263	73–3537	37	<i>cry3Bb2</i>	<i>cryIIIC(b)</i>	U31633	144–2099	23
<i>cry1Ab7</i>	<i>cryIA(b)</i>	X13233	1–3465	36	<i>cry3Ca1</i>	<i>cryIIID</i>	X59797	232–2178	59
<i>cry1Ab8</i>	<i>cryIA(b)</i>	M16463	157–3621	69	<i>cry4Aa1</i>	<i>cryIVA</i>	Y00423	1–3540	121
<i>cry1Ab9</i>	<i>cryIA(b)</i>	X54939	73–3537	13	<i>cry4Aa2</i>	<i>cryIVA</i>	D00248	393–3935	95
<i>cry1Ab10</i>	<i>cryIA(b)</i>	A29125	— <sup>b</sup>	28	<i>cry4Ba1</i>	<i>cryIVB</i>	X07423	157–3564	16
<i>cry1Ac1</i>	<i>cryIA(c)</i>	M11068	388–3921	3	<i>cry4Ba2</i>	<i>cryIVB</i>	X07082	151–3558	112
<i>cry1Ac2</i>	<i>cryIA(c)</i>	M35524	239–3769	117	<i>cry4Ba3</i>	<i>cryIVB</i>	M20242	526–3930	125
<i>cry1Ac3</i>	<i>cryIA(c)</i>	X54159	339–>2192	18	<i>cry4Ba4</i>	<i>cryIVB</i>	D00247	461–3865	95
<i>cry1Ac4</i>	<i>cryIA(c)</i>	M73249	1–3534	84	<i>cry5Aa1</i>	<i>cryVA(a)</i>	L07025	1–>4155	102
<i>cry1Ac5</i>	<i>cryIA(c)</i>	M73248	1–3531	83	<i>cry5Ab1</i>	<i>cryVA(b)</i>	L07026	1–>3867	67
<i>cry1Ac6</i>	<i>cryIA(c)</i>	U43606	1–>1821	63	<i>cry5Ac1</i>		I34543	1–>3660	76
<i>cry1Ac7</i>	<i>cryIA(c)</i>	U87793	976–4509	38	<i>cry5Ba1</i>	PS86Q3	U19725	1–>3735	76
<i>cry1Ac8</i>	<i>cryIA(c)</i>	U87397	153–3686	71	<i>cry6Aa1</i>	<i>cryVIA</i>	L07022	1–>1425	68
<i>cry1Ac9</i>	<i>cryIA(c)</i>	U89872	388–3921	33	<i>cry6Ba1</i>	<i>cryVIB</i>	L07024	1–>1185	67
<i>cry1Ac10</i>		AJ002514	388–3921	107	<i>cry7Aa1</i>	<i>cryIIIC</i>	M64478	184–3597	58
<i>cry1Ad1</i>	<i>cryIA(c)</i>	M73250	1–3537	79	<i>cry7Ab1</i>	<i>cryIIIC(b)</i>	U04367	1–>3414	75
<i>cry1Ae1</i>	<i>cryIA(e)</i>	M65252	81–3623	60	<i>cry7Ab2</i>	<i>cryIIIC(c)</i>	U04368	1–>3414	75
<i>cry1Afl</i>	<i>icp</i>	U82003	172–>2905	49	<i>cry8Aa1</i>	<i>cryIIIE</i>	U04364	1–>3471	29
<i>cry1Ba1</i>	<i>cryIB</i>	X06711	1–3684	10	<i>cry8Ba1</i>	<i>cryIIIG</i>	U04365	1–>3507	66
<i>cry1Ba2</i>		X95704	186–3869	105	<i>cry8Ca1</i>	<i>cryIIIF</i>	U04366	1–3447	70
<i>cry1Bb1</i>	ET5	L32020	67–3753	25	<i>cry9Aa1</i>	<i>cryIG</i>	X58120	5807–9274	104
<i>cry1Bc1</i>	<i>cryIB(c)</i>	Z46442	141–3839	6	<i>cry9Aa2</i>	<i>cryIG</i>	X58534	385–>3837	32
<i>cry1Ba1</i>	<i>cryEI</i>	U70726		12	<i>cry9Ba1</i>	<i>cryIX</i>	X75019	26–3488	97
<i>cry1Ca1</i>	<i>cryIC</i>	X07518	47–3613	45	<i>cry9Ca1</i>	<i>cryIH</i>	Z37527	2096–5569	57
<i>cry1Ca2</i>	<i>cryIC</i>	X13620	241–>2711	88	<i>cry9Da1</i>	N141	D85560	47–3553	4
<i>cry1Ca3</i>	<i>cryIC</i>	M73251	1–3570	79	<i>cry9Da2</i>		AF042733	<1–>1937	122
<i>cry1Ca4</i>	<i>cryIC</i>	A27642	234–3800	114	<i>cry10Aa1</i>	<i>cryIVC</i>	M12662	941–2965	111
<i>cry1Ca5</i>	<i>cryIC</i>	X96682	1–>2268	106	<i>cry11Aa1</i>	<i>cryIVD</i>	M31737	41–1969	21
<i>cry1Ca6</i>	<i>cryIC</i>	X96683	1–>2268	106	<i>cry11Aa2</i>	<i>cryIVD</i>	M22860	<1–235	2
<i>cry1Ca7</i>	<i>cryIC</i>	X96684	1–>2268	106	<i>cry11Ba1</i>	Jeg80	X86902	64–2238	19
<i>cry1Cb1</i>	<i>cryIC(b)</i>	M97880	296–3823	48	<i>cry11Bb1</i>	94 kDa	AF017416		72
<i>cry1Da1</i>	<i>cryID</i>	X54160	264–3758	42	<i>cry12Aa1</i>	<i>cryVB</i>	L07027	1–>3771	67
<i>cry1Db1</i>	<i>prtB</i>	Z22511	241–3720	56	<i>cry13Aa1</i>	<i>cryVC</i>	L07023	1–2409	90
<i>cry1Ea1</i>	<i>cryIE</i>	X53985	130–3642	115	<i>cry14Aa1</i>	<i>cryVD</i>	U13955	1–3558	77
<i>cry1Ea2</i>	<i>cryIE</i>	X56144	1–3513	7	<i>cry15Aa1</i>	34kDa	M76442	1036–2055	11
<i>cry1Ea3</i>	<i>cryIE</i>	M73252	1–3513	82	<i>cry16Aa1</i>	<i>cbm71</i>	X94146	158–1996	5
<i>cry1Ea4</i>		U94323	388–3900	47	<i>cry17Aa1</i>	<i>cbm72</i>	X99478	12–1865	5
<i>cry1Eb1</i>	<i>cryIE(b)</i>	M73253	1–3522	81	<i>cry18Aa1</i>	<i>cryBPI</i>	X99049	743–2860	126
<i>cry1Fa1</i>	<i>cryIF</i>	M63897	478–3999	14	<i>cry19Aa1</i>	Jeg65	Y07603	719–2662	86
<i>cry1Fa2</i>	<i>cryIF</i>	M73254	1–3525	80	<i>cry19Ba1</i>		D88381		87
<i>cry1Fb1</i>	<i>prtD</i>	Z22512	483–4004	56	<i>cry20Aa1</i>	86kDa	U82518	60–2318	61
<i>cry1Ga1</i>	<i>prtA</i>	Z22510	67–3564	56	<i>cry21Aa1</i>		I32932	1–3501	74
<i>cry1Ga2</i>	<i>cryIM</i>	Y09326	692–4210	96	<i>cry22Aa1</i>		I34547	1–2169	76
<i>cry1Gb1</i>	<i>cryH2</i>	U70725		12					
<i>cry1Ha1</i>	<i>prtC</i>	Z22513	530–4045	56					
<i>cry1Hb1</i>		U35780	728–4195	53					
<i>cryIIa1</i>	<i>cryV</i>	X62821	355–2511	108					
<i>cryIIa2</i>	<i>cryV</i>	M98544	1–2157	34					
<i>cryIIa3</i>	<i>cryV</i>	L36338	279–2435	100	<i>cyt1Aa1</i>	<i>cytA</i>	X03182	140–886	118
<i>cryIIa4</i>	<i>cryV</i>	L49391	61–2217	54	<i>cyt1Aa2</i>	<i>cytA</i>	X04338	509–1255	120
<i>cryIIa5</i>	<i>cryV159</i>	Y08920	524–2680	94	<i>cyt1Aa3</i>	<i>cytA</i>	Y00135	36–782	26
<i>cryIIb1</i>	<i>cryV465</i>	U07642	237–2393	100	<i>cyt1Aa4</i>	<i>cytA</i>	M35968	67–813	30
<i>cryIIa1</i>	ET4	L32019	99–3519	25	<i>cyt1Ab1</i>	<i>cytM</i>	X98793	28–777	109
<i>cryIIb1</i>	ET1	U31527	177–3686	116	<i>cyt1Ba1</i>		U37196	1–795	78
<i>cryIKa1</i>		U28801	451–4098	52	<i>cyt2Aa1</i>	<i>cytB</i>	Z14147	270–1046	51
<i>cry2Aa1</i>	<i>cryIIA</i>	M31738	156–2054	20	<i>cyt2Ba1</i>	"cytB"	U52043	287–655	35
<i>cry2Aa2</i>	<i>cryIIA</i>	M23723	1840–3738	123	<i>cyt2Bb1</i>		U82519	416–1204	15
<i>cry2Aa3</i>		D86064	2007–3911	89					
<i>cry2Ab1</i>	<i>cryIIB</i>	M23724	1–1899	123					

<sup>a</sup> The symbols < and > indicate that the coding region extends up- or downstream, respectively, from the known sequence data.<sup>b</sup> Only the polypeptide sequence has been reported.




FIG. 1. Phylogram demonstrating amino acid sequence identity among Cry and Cyt proteins. This phylogenetic tree is modified from a TREEVIEW visualization of NEIGHBOR treatment of a CLUSTAL W multiple alignment and distance matrix of the full-length toxin sequences, as described in the text. The gray vertical bars demarcate the four levels of nomenclature ranks. Based on the low percentage of identical residues and the absence of any conserved sequence blocks in multiple-sequence alignments, the lower four lineages are not treated as part of the main toxin family, and their nodes have been replaced with dashed horizontal lines in this figure.

had significant branch points deeper in the tree than the chosen primary rank in the nomenclature. This sort of analysis was rejected as unsuitable for the purposes of Cry nomenclature due to the generally ragged branch lengths it produced and the requirement for the careful choice of an outgroup.

An alternative method of clustering protein sequences, ca-

pable of handling sequences that are quite diverse, is parsimony analysis. A consensus tree generated from 100 bootstraps of such an analysis displaces the two incomplete Cry1 sequences (Cry1Bd and Cry1Af) and the two Cry1 sequences lacking the C-terminal protoxin segments (Cry1Ia and Cry1Ib) into a region of the tree populated with such shortened se-

quences (not shown). With the further exceptions of Cry12A being interjected into the Cry5 cluster and a number of sequences besides Cry6B clustering higher in the tree than Cry6A, the proposed nomenclature successfully reflects the grouping of sequences provided by this method of analysis as well.

As noted above, the usual distance metrics for phylogenetic analysis account for multiple substitutions per site; most commonly, the Dayhoff PAM metric is used. When this distance metric was applied to the alignment used to make Fig. 1, a large number of the sequence pairs were found to have infinite distance. Therefore, the main Cry lineage and the Cyt lineage were separately aligned, the distances were calculated, and the distance matrices were clustered by using the FITCH program (of the PHYLIP software package). This method of analysis revealed several strongly associated groups of sequences (>90% of trees) in the main Cry lineage that extend deeper into the tree than the primary rank assigned in the proposed nomenclature: Cry1; Cry3; Cry4; Cry7; the Cry5, Cry12-Cry13-Cry14-Cry21 group; the Cry8-Cry9 group; the Cry10-Cry19 group; the Cry16-Cry17 group; and the Cry2-Cry11-Cry18 group. Many of these groups, however, were separated by branch points that were either nonmajority or were found <60% of the time; thus, the arrangement of these groups would be likely to change with additional sequence additions. At the secondary rank, the only anomaly with respect to the proposed nomenclature was the interjection of the Cry1Ia and Cry1Ib sequences into the Cry1B group. This effect may be due to an artificially reduced distance between the Cry1I sequences and the incomplete Cry1Bd sequence caused by the particular distance metric used. The Cyt lineage sequences were separated into the expected two primary rank groups that separate into the expected secondary rank groupings. This more standard phylogenetic approach also suffers from an accentuated visual disorientation of uneven branch lengths and shortening of the more closely related branches, especially at the tertiary rank (lowercase letter), where a great deal of comparative work has been done among the Cry1 toxins.

In summary, the proposed nomenclature uses readily available software that can be easily interpreted by investigators in the field and meets their needs as well as, or better than, alternative methods of analysis and presentation. When the holotype toxins were analyzed by alternative phylogenetic methods, the hierarchy implied by the nomenclature was essentially consistent with the resulting phylogenetic clustering, and the few exceptions were largely explainable by known properties of the sequences in question.

#### ACKNOWLEDGMENTS

The BGSC is supported by National Science Foundation grant DBI-9319712 and by industrial sponsorships.

#### REFERENCES

- Adams, L. F., S. Mathewes, P. O'Hara, A. Petersen, and H. Gürtler. 1994. Elucidation of the mechanism of CryIIIA overproduction in a mutagenized strain of *Bacillus thuringiensis* var. *tenebrionis*. *Mol. Microbiol.* 14:381-389.
- Adams, L. F., J. E. Visick, and H. R. Whiteley. 1989. A 20-kilodalton protein is required for efficient production of the *Bacillus thuringiensis* subsp. *israelensis* 27-kilodalton crystal protein in *Escherichia coli*. *J. Bacteriol.* 171:521-530.
- Adang, M. J., M. J. Staver, T. A. Rocheleau, J. Leighton, R. F. Barker, and D. V. Thompson. 1985. Characterized full-length and truncated plasmid clones of the crystal protein of *Bacillus thuringiensis* subsp. *kurstaki* HD-73 and their toxicity to *Manduca sexta*. *Gene* 36:289-300.
- Asano, S. I., Y. Nukumizu, H. Bando, T. Iizuka, and T. Yamamoto. 1997. Cloning of novel enterotoxin genes from *Bacillus cereus* and *Bacillus thuringiensis*. *Appl. Environ. Microbiol.* 63:1054-1057.
- Barloy, F., A. Delécluse, L. Nicolas, and M.-M. Lecadet. 1996. Cloning and expression of the first anaerobic toxin gene from *Clostridium bifementans* subsp. *malaysia*, encoding a new mosquitocidal protein with homologies to *Bacillus thuringiensis* delta-endotoxins. *J. Bacteriol.* 178:3099-3105.
- Bishop, A. H. 1994. Unpublished observation.
- Bossé, M., L. Masson, and R. Brousseau. 1990. Nucleotide sequence of a novel crystal protein gene isolated from *Bacillus thuringiensis* subspecies *kenyae*. *Nucleic Acids Res.* 18:7443.
- Bradley, D., M. A. Harkey, M.-K. Kim, D. Biever, and L. S. Bauer. 1995. The insecticidal CryIB protein of *Bacillus thuringiensis* ssp. *thuringiensis* has dual specificity to coleopteran and lepidopteran larvae. *J. Invertebr. Pathol.* 65:162-173.
- Bravo, A. 1997. Phylogenetic relationships of *Bacillus thuringiensis*  $\delta$ -endotoxin family proteins and their functional domains. *J. Bacteriol.* 179:2793-2801.
- Brizzard, B. L., and H. R. Whiteley. 1988. Nucleotide sequence of an additional crystal protein gene cloned from *Bacillus thuringiensis* subsp. *thuringiensis*. *Nucleic Acids Res.* 16:2723-2724.
- Brown, K. L., and H. R. Whiteley. 1992. Molecular characterization of two novel crystal protein genes from *Bacillus thuringiensis* subsp. *thompsoni*. *J. Bacteriol.* 174:549-557.
- Chak, K. F. 1996. Unpublished observation.
- Chak, K. F., and J. C. Chen. 1993. Complete nucleotide sequence and identification of a putative promoter region for the expression in *Escherichia coli* of the *cryIA(b)* gene from *Bacillus thuringiensis* var. *aizawai* HD133. *Proc. Natl. Sci. Coun. Repub. China* 17:7-14.
- Chambers, J. A., A. Jelen, M. P. Gilbert, C. S. Jany, T. B. Johnson, and C. Gawron-Burke. 1991. Isolation and characterization of a novel insecticidal crystal protein gene from *Bacillus thuringiensis* subsp. *aizawai*. *J. Bacteriol.* 173:3966-3976.
- Cheong, H., and S. S. Gill. 1997. Cloning and characterization of a cytolytic and mosquitocidal  $\delta$ -endotoxin from *Bacillus thuringiensis* subsp. *jegathesan*. *Appl. Environ. Microbiol.* 63:3254-3260.
- Chungjatupornchai, W., H. Höfte, J. Seurinck, C. Angsuthanasombat, and M. Vaec. 1988. Common features of *Bacillus thuringiensis* toxins specific for *Diptera* and *Lepidoptera*. *Eur. J. Biochem.* 173:9-16.
- Dankocsik, C., W. P. Donovan, and C. S. Jany. 1990. Activation of a cryptic crystal protein gene of *Bacillus thuringiensis* subspecies *kurstaki* by gene fusion and determination of the crystal protein insecticidal specificity. *Mol. Microbiol.* 4:2087-2094.
- Dardenne, F., J. Seurinck, B. Lambert, and M. Peferoen. 1990. Nucleotide sequence and deduced amino acid sequence of a *cryIA(c)* gene variant from *Bacillus thuringiensis*. *Nucleic Acids Res.* 18:5546.
- Delécluse, A., M.-L. Rosso, and A. Ragni. 1995. Cloning and expression of a novel toxin gene from *Bacillus thuringiensis* subsp. *jegathesan* encoding a highly mosquitocidal protein. *Appl. Environ. Microbiol.* 61:4230-4235.
- Donovan, W. P., C. C. Dankocsik, M. P. Gilbert, W. C. Gawron-Burke, R. R. Groat, and B. C. Carlton. 1988. Amino acid sequence and entomocidal activity of the P2 crystal protein. An insect toxin from *Bacillus thuringiensis* var. *kurstaki*. *J. Biol. Chem.* 263:561-567. (Author's correction, 263:4740.)
- Donovan, W. P., C. Dankocsik, and M. P. Gilbert. 1988. Molecular characterization of a gene encoding a 72-kilodalton mosquito-toxic crystal protein from *Bacillus thuringiensis* subsp. *israelensis*. *J. Bacteriol.* 170:4732-4738.
- Donovan, W. P., J. M. González, Jr., M. P. Gilbert, and C. Dankocsik. 1988. Isolation and characterization of EG2158, a new strain of *Bacillus thuringiensis* toxic to coleopteran larvae, and nucleotide sequence of the toxin gene. *Mol. Gen. Genet.* 214:365-372.
- Donovan, W. P., M. J. Rupar, and A. C. Slaney. January 1995. U.S. patent 5,378,625.
- Donovan, W. P., M. J. Rupar, A. C. Slaney, T. Malvar, M. C. Gawron-Burke, and T. B. Johnson. 1992. Characterization of two genes encoding *Bacillus thuringiensis* insecticidal crystal proteins toxic to *Coleoptera* species. *Appl. Environ. Microbiol.* 58:3921-3927.
- Donovan, W. P., Y. Tan, C. S. Jany, and J. M. González, Jr. June 1994. U.S. patent 5,322,687.
- Earp, D. J., and D. J. Ellar. 1987. *Bacillus thuringiensis* var. *morrisoni* strain PG14: nucleotide sequence of a gene encoding a 27 kDa crystal protein. *Nucleic Acids Res.* 15:3619.
- Felsenstein, J. 1989. PHYLIP—phylogeny inference package (version 2). *Cladistics* 5:164-166.
- Fischhoff, D. A., K. S. Bowditch, F. J. Perlak, P. G. Marrone, S. H. McCormick, J. G. Niedermeyer, D. A. Dean, K. Kusano-Kretzmer, E. J. Mayer, D. E. Rochester, S. G. Rogers, and R. T. Fraley. 1987. Insect tolerant transgenic tomato plants. *Bio/Technology* 5:807-813.
- Foncerrada, L., A. J. Sick, and J. M. Payne. August 1992. European Patent Office no. EP 0498537.
- Galjart, N. J., N. Sivasubramanian, and B. A. Federici. 1987. Plasmid location, cloning and sequence analysis of the gene encoding a 23-kilodalton cytolytic protein from *Bacillus thuringiensis* subsp. *morrisoni* (PG-14). *Curr. Microbiol.* 16:171-177.
- Geiser, M., S. Schweitzer, and C. Grimm. 1986. The hypervariable region in the genes coding for entomopathogenic crystal proteins of *Bacillus thurin-*

- giensis*: nucleotide sequence of the kurhd1 gene of subsp. *kurstaki* HD1. Gene 48:109–118.
32. Gleave, A. P., R. J. Hedges, and A. H. Broadwell. 1992. Identification of an insecticidal crystal protein from *Bacillus thuringiensis* DSIR517 with significant sequence differences from previously described toxins. J. Gen. Microbiol. 138:55–62.
  33. Gleave, A. P., R. J. Hedges, A. H. Broadwell, and P. J. Wigley. 1992. Cloning and nucleotide sequence of an insecticidal crystal protein gene from *Bacillus thuringiensis* DSIR732 active against three species of leafroller Lepidoptera *Tortricidae*. N. Z. J. Crop Hortic. Sci. 20:27–36.
  34. Gleave, A. P., R. Williams, and R. J. Hedges. 1993. Screening by polymerase chain reaction of *Bacillus thuringiensis* serotypes for the presence of *cryV*-like insecticidal protein genes and characterization of a *cryV* gene cloned from *B. thuringiensis* subsp. *kurstaki*. Appl. Environ. Microbiol. 59:1683–1687.
  35. Guerchicoff, A., R. U. Ugalde, and C. P. Rubinstein. 1997. Identification and characterization of a previously undescribed *cyt* gene in *Bacillus thuringiensis* subsp. *israelensis*. Appl. Environ. Microbiol. 63:2716–2721.
  36. Haider, M. Z., and D. J. Ellar. 1988. Nucleotide sequence of a *Bacillus thuringiensis* aizawai ICI entomocidal crystal protein gene. Nucleic Acids Res. 16:10927.
  37. Hefford, M. A., R. Brousseau, G. Préfontaine, Z. Hanna, J. A. Condie, and P. C. K. Lau. 1987. Sequence of a lepidopteran toxin gene of *Bacillus thuringiensis* subsp. *kurstaki* NRD-12. J. Biotechnol. 6:307–322.
  38. Herrera, G., S. J. Snyman, and J. A. Thomson. 1994. Construction of a bioinsecticidal strain of *Pseudomonas fluorescens* active against the sugarcane borer, *Eldana saccharina*. Appl. Environ. Microbiol. 60:682–690.
  39. Herrnstadt, C., T. E. Gilroy, D. A. Sobieski, B. D. Bennett, and F. H. Gaertner. 1987. Nucleotide sequence and deduced amino acid sequence of a coleopteran-active delta-endotoxin gene from *Bacillus thuringiensis* subsp. *san diego*. Gene 57:37–46.
  40. Höfte, H., H. de Greve, J. Seurinck, S. Jansens, J. Mahillon, C. Ampe, J. Vandekerckhove, M. van Montagu, M. Zabeau, and M. Vaeck. 1986. Structural and functional analysis of a cloned delta endotoxin of *Bacillus thuringiensis* berliner 1715. Eur. J. Biochem. 161:273–280.
  41. Höfte, H., J. Seurinck, A. Van Houtven, and M. Vaeck. 1987. Nucleotide sequence of a gene encoding an insecticidal protein of *Bacillus thuringiensis* var. *tenebrionis* toxic against Coleoptera. Nucleic Acids Res. 15:7183.
  42. Höfte, H., P. Soetaert, S. Jansens, and M. Peferoen. 1990. Nucleotide sequence and deduced amino acid sequence of a new Lepidoptera-specific crystal protein gene from *Bacillus thuringiensis*. Nucleic Acids Res. 18:5545.
  43. Höfte, H., J. Van Rie, S. Jansens, A. Van Houtven, H. Vanderbruggen, and M. Vaeck. 1988. Monoclonal antibody analysis and insecticidal spectrum of three types of lepidopteran-specific insecticidal crystal proteins of *Bacillus thuringiensis*. Appl. Environ. Microbiol. 54:2010–2017.
  44. Höfte, H., and H. R. Whiteley. 1989. Insecticidal crystal proteins of *Bacillus thuringiensis*. Microbiol. Rev. 53:242–255.
  45. Honée, G., T. van der Salm, and B. Visser. 1988. Nucleotide sequence of crystal protein gene isolated from *B. thuringiensis* subspecies *entomocidus* 60.5 coding for a toxin highly active against *Spodoptera* species. Nucleic Acids Res. 16:6240.
  46. Hori, H., K. Suzuki, K. Ogiwara, M. Minami, H. Himejima, K. Sakanaka, Y. Kaji, S. Asano, R. Sato, M. Ohba, and H. Iwahana. 1992. Presented at the XXVth Annual Meeting of the Society for Invertebrate Pathology, Heidelberg, Germany.
  47. Ibarra, J. 1997. Unpublished observation.
  48. Kalman, S., K. L. Kiehne, J. L. Libs, and T. Yamamoto. 1993. Cloning of a novel *cryIC*-type gene from a strain of *Bacillus thuringiensis* subsp. *galleariae*. Appl. Environ. Microbiol. 59:1131–1137.
  49. Kang, S. K., H. S. Kim, and Y. M. Yu. 1997. Unpublished observation.
  50. Kondo, S., N. Tamura, A. Kunitate, M. Hattori, A. Akashi, and I. Ohmori. 1987. Cloning and nucleotide sequencing of two insecticidal  $\delta$ -endotoxin genes from *Bacillus thuringiensis* var. *kurstaki* HD-1 DNA. Agric. Biol. Chem. 51:455–463.
  51. Koni, P. A., and D. J. Ellar. 1993. Cloning and characterization of a novel *Bacillus thuringiensis* cytolytic delta-endotoxin. J. Mol. Biol. 229:319–327.
  52. Koo, B. T. 1995. Unpublished observation.
  53. Koo, B. T., S. H. Park, S. K. Choi, B. S. Shin, J. I. Kim, and J. H. Yu. 1995. Cloning of a novel crystal protein gene *cryIK* from *Bacillus thuringiensis* subsp. *morisoni*. FEMS Microbiol. Lett. 134:159–164.
  54. Kostichka, K., G. W. Warren, M. Mullins, A. D. Mullins, J. A. Craig, M. G. Koziel, and J. J. Estruch. 1996. Cloning of a *cryV*-type insecticidal protein gene from *Bacillus thuringiensis*: the *cryV*-encoded protein is expressed early in stationary phase. J. Bacteriol. 178:2141–2144.
  55. Kronstad, J. W., and H. R. Whiteley. 1986. Three classes of homologous *Bacillus thuringiensis* crystal-protein genes. Gene 43:29–40.
  56. Lambert, B. 1993. Unpublished observation.
  57. Lambert, B., L. Buysse, C. Decock, S. Jansens, C. Piens, B. Saey, J. Seurinck, K. Van Audenhove, J. Van Rie, A. Van Vliet, and M. Peferoen. 1996. A *Bacillus thuringiensis* insecticidal protein with a high activity against members of the family Noctuidae. Appl. Environ. Microbiol. 62:80–86.
  58. Lambert, B., H. Höfte, K. Annys, S. Jansens, P. Soetaert, and M. Peferoen. 1992. Novel *Bacillus thuringiensis* insecticidal crystal protein with a silent activity against coleopteran larvae. Appl. Environ. Microbiol. 58:2536–2542.
  59. Lambert, B., W. Theunis, R. Agouda, K. Van Audenhove, D. C., S. Jansens, J. Seurinck, and M. Peferoen. 1992. Nucleotide sequence of gene *cryIIID* encoding a novel coleopteran-active crystal protein from strain BT1109P of *Bacillus thuringiensis* subsp. *kurstaki*. Gene 110:131–132.
  60. Lee, C.-S., and A. I. Aronson. 1991. Cloning and analysis of  $\delta$ -endotoxin genes from *Bacillus thuringiensis* subsp. *alesti*. J. Bacteriol. 173:6635–6638.
  61. Lee, H.-K., and S. S. Gill. 1997. Molecular cloning and characterization of a novel mosquitocidal protein gene from *Bacillus thuringiensis* subsp. *fukuokaensis*. Appl. Environ. Microbiol. 63:4664–4670.
  62. Masson, L., P. Marcotte, G. Préfontaine, and R. Brousseau. 1989. Nucleotide sequence of a gene cloned from *Bacillus thuringiensis* subspecies *entomocidus* coding for an insecticidal protein toxic for *Bombyx mori*. Nucleic Acids Res. 17:446.
  63. Masson, L., A. Mazza, L. Gringorten, D. Baines, V. Aneliunas, and R. Brousseau. 1994. Specificity domain localization of *Bacillus thuringiensis* insecticidal toxins is highly dependent on the bioassay system. Mol. Microbiol. 14:851–860.
  64. McLinden, J. H., J. R. Sabourin, B. D. Clark, D. R. Gensler, W. E. Workman, and D. H. Dean. 1985. Cloning and expression of an insecticidal k-73 type crystal protein gene from *Bacillus thuringiensis* var. *kurstaki* to *Escherichia coli*. Appl. Environ. Microbiol. 50:623–628.
  65. McPherson, S. A., F. J. Perlak, R. L. Fuchs, P. G. Marrone, P. B. Lavrik, and D. A. Fischhoff. 1988. Characterization of the coleopteran-specific protein gene of *Bacillus thuringiensis* var. *tenebrionis*. Bio/Technology 6:61–66.
  66. Michaels, T. E., K. E. Narva, and L. Foncerrada. August 1993. World Intellectual Property Organization patent WO 93/15206.
  67. Narva, K. E., J. M. Payne, G. E. Schwab, L. A. Hickle, T. Galasan, and A. J. Sick. December 1991. European Patent Office no. EP 0462721.
  68. Narva, K. E., G. E. Schwab, T. Galasan, and J. M. Payne. August 1993. U.S. patent 5,236,843.
  - 68a. Nelson, D. R., L. Koymans, T. Kamataki, J. J. Stegeman, R. Feyereisen, D. J. Waxman, M. R. Waterman, O. Gotoh, M. J. Coon, R. W. Estabrook, I. C. Gunsalus, and D. W. Nebert. 1996. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1–42.
  69. Oeda, K., K. Oshie, M. Shimizu, K. Nakamura, H. Yamamoto, I. Nakayama, and H. Ohkawa. 1987. Nucleotide sequence of the insecticidal protein gene of *Bacillus thuringiensis* strain *aizawai* IPL7 and its high-level expression in *Escherichia coli*. Gene 53:113–119.
  70. Ogiwara, K., H. Hori, M. Minami, K. Takeuchi, R. Sato, M. Ohba, and H. Iwahana. 1995. Nucleotide sequence of the gene encoding novel delta-endotoxin from *Bacillus thuringiensis* serovar *japonensis* strain Buibui specific to scarabaeid beetles. Curr. Microbiol. 30:227–235.
  71. Omolo, E. O., J. M. D. O. E. O., and J. A. Thomson. 1997. Cloning and expression of a *Bacillus thuringiensis* (L1-2) gene encoding a crystal protein active against *Glossina morsitans morsitans* and *Chilo partellus*. Curr. Microbiol. 34:118–121.
  72. Ordaz, S. Unpublished observation.
  73. Page, R. D. M. 1996. TREEVIEW: an application to display phylogenetic trees on personal computers. CABIOS 12:357–358.
  74. Payne, J. M., K. E. Narva, and J. Fu. December 1996. U.S. patent 5,589,382.
  75. Payne, J. M., and J. M. Fu. February 1994. U.S. patent 5,286,486.
  76. Payne, J. M., M. E. Kennedy, J. B. Randall, H. Meier, H. J. Uick, L. Foncerrada, H. E. Schnepf, G. E. Schwab, and J. Fu. January 1997. U.S. patent 5,596,071.
  77. Payne, J. M., and K. E. Narva. July 1994. World Intellectual Property Organization patent WO 94/16079.
  78. Payne, J. M., K. E. Narva, K. A. Uyeda, C. J. Stalder, and T. E. Michaels. July 1995. U.S. patent 5,436,002.
  79. Payne, J. M., and A. J. Sick. September 1993. U.S. patent 5,246,852.
  80. Payne, J. M., and A. J. Sick. February 1993. U.S. patent 5,188,960.
  81. Payne, J. M., and A. J. Sick. April 1993. U.S. patent 5,206,166.
  82. Payne, J. M., and A. J. Sick. August 1991. U.S. patent 5,039,523.
  83. Payne, J. M., A. J. Sick, and M. Thompson. August 1992. U.S. patent 5,135,867.
  84. Payne, J. M., G. G. Soares, H. W. Talbot, and T. C. Olson. October 1991. U.S. patent 4,990,332.
  85. Peferoen, M., B. Lambert, and H. Joos. August 1990. European patent Office no. EP 0382990-A1.
  86. Rosso, M. L., and A. Delecluse. 1997. Contribution of the 65-kilodalton protein encoded by the cloned gene *cry19A* to the mosquitocidal activity of *Bacillus thuringiensis* subsp. *jagathesan*. Appl. Environ. Microbiol. 63:4449–4455.
  87. Saitoh, H. 1996. Unpublished observation.
  88. Sanchis, V., D. Lereclus, G. Menou, J. Chauvaux, S. Guo, and M.-M. Lecadet. 1989. Nucleotide sequence and analysis of the N-terminal coding region of the *Spodoptera*-active  $\delta$ -endotoxin gene of *Bacillus thuringiensis* *aizawai* 7.29. Mol. Microbiol. 3:229–238.

89. Sasaki, J., S. Asano, N. Hashimoto, B.-W. Lay, S. Hastowo, H. Bando, and T. Iizuka. 1997. Characterization of a *cry2A* gene cloned from an isolate of *Bacillus thuringiensis* serovar *sotto*. *Curr. Microbiol.* 35:1–8.
90. Schnepf, H. E., G. E. Schwab, J. M. Payne, K. E. Narva, and L. Fonceerrada. November 1992. World Intellectual Property Organization patent WO 92/19739.
91. Schnepf, H. E., and H. R. Whiteley. 1981. Cloning and expression of the *Bacillus thuringiensis* crystal protein gene in *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* 78:2893–2897.
92. Schnepf, H. E., H. C. Wong, and H. R. Whiteley. 1985. The amino acid sequence of a crystal protein from *Bacillus thuringiensis* deduced from the DNA base sequence. *J. Biol. Chem.* 260:6264–6272.
93. Sekar, V., D. V. Thompson, M. J. Maroney, R. G. Bookland, and M. J. Adang. 1987. Molecular cloning and characterization of the insecticidal crystal protein gene of *Bacillus thuringiensis* var. *tenebrionis*. *Proc. Natl. Acad. Sci. USA* 84:7036–7040.
94. Selvapandyan, A. 1996. Unpublished observation.
95. Sen, K., G. Honda, N. Koyama, M. Nishida, A. Neki, H. Sakai, M. Himeno, and T. Komano. 1988. Cloning and nucleotide sequences of the two 130 kDa insecticidal protein genes of *Bacillus thuringiensis* var. *israelensis*. *Agric. Biol. Chem.* 52:873–878.
96. Shevelev, A. B., Y. N. Kogan, A. M. Busheva, E. J. Voronina, D. V. Tebrikov, S. I. Novikova, G. G. Chestukhina, V. Kubshinov, E. Pehu, and V. M. Stepanov. 1997. A novel delta-endotoxin gene *cryIM* from *Bacillus thuringiensis* subsp. *wuhanensis*. *FEBS Lett.* 404:148–152.
97. Shevelev, A. B., M. A. Svarinsky, A. I. Karasin, Y. N. Kogan, G. G. Chestukhina, and V. M. Stepanov. 1993. Primary structure of *cryX*, the novel delta-endotoxin-related gene from *Bacillus thuringiensis* spp. *galleriae*. *FEBS Lett.* 336:79–82.
98. Shibano, Y., A. Yamagata, N. Nakamura, T. Iizuka, H. Sugisaki, and M. Takanami. 1985. Nucleotide sequence coding for the insecticidal fragment of the *Bacillus thuringiensis* crystal protein. *Gene* 34:243–251.
99. Shimizu, M., K. Oshie, K. Nakamura, Y. Takada, K. Oeda, and H. Ohkawa. 1988. Cloning and expression in *Escherichia coli* of the 135-kDa insecticidal protein gene from *Bacillus thuringiensis* subsp. *aizawai* IPL7. *Agric. Biol. Chem.* 52:1565–1573.
100. Shin, B.-S., S.-H. Park, S.-K. Choi, B.-T. Koo, S.-T. Lee, and J.-I. Kim. 1995. Distribution of *cryV*-type insecticidal protein genes in *Bacillus thuringiensis* and cloning of *cryV*-type genes from *Bacillus thuringiensis* subsp. *kurstaki* and *Bacillus thuringiensis* subsp. *entomocidus*. *Appl. Environ. Microbiol.* 61:2402–2407.
101. Sick, A., F. Gaertner, and A. Wong. 1990. Nucleotide sequence of a coleopteran-active toxin gene from a new isolate of *Bacillus thuringiensis* subsp. *tolworthi*. *Nucleic Acids Res.* 18:1305.
102. Sick, A. J., G. E. Schwab, and J. M. Payne. January 1994. U.S. patent 05281530.
103. Smith, G. P., and D. J. Ellar. 1994. Mutagenesis of two surface-exposed loops of the *Bacillus thuringiensis* CryIC  $\delta$ -endotoxin affects insecticidal specificity. *Biochem. J.* 302:611–616.
104. Smulevitch, S. V., A. L. Osterman, A. B. Shevelev, S. V. Kaluger, A. I. Karasin, R. M. Kadyrov, O. P. Zagnitko, G. G. Chestukhina, and V. M. Stepanov. 1991. Nucleotide sequence of a novel delta-endotoxin gene *cryIG* of *Bacillus thuringiensis* ssp. *galleriae*. *FEBS Lett.* 293:25–28.
105. Soetaert, P. 1996. Unpublished observation.
106. Strizhov, N. 1996. Unpublished observation.
107. Sun, M. 1997. Unpublished observation.
108. Tailor, R., J. Tippet, G. Gibb, S. Pells, D. Pike, L. Jordon, and S. Ely. 1992. Identification and characterization of a novel *Bacillus thuringiensis* delta-endotoxin entomocidal to coleopteran and lepidopteran larvae. *Mol. Microbiol.* 6:1211–1217.
109. Thiery, L., A. Delécluse, M. C. Tamayo, and S. Orduz. 1997. Identification of a gene for Cyt1A-like hemolysin from *Bacillus thuringiensis* subsp. *medellin* and expression in a crystal-negative *B. thuringiensis* strain. *Appl. Environ. Microbiol.* 63:468–473.
110. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res.* 22:4673–4680.
111. Thorne, L., F. Garduno, T. Thompson, D. Decker, M. Zounes, M. Wild, A. M. Walfield, and T. J. Pollock. 1986. Structural similarity between the Lepidoptera- and Diptera-specific insecticidal endotoxin genes of *Bacillus thuringiensis* subsp. "*kurstaki*" and "*israelensis*." *J. Bacteriol.* 166:801–811.
112. Tungpradubkul, S., C. Settasatien, and S. Panyim. 1988. The complete nucleotide sequence of a 130 kDa mosquito-larvicidal delta-endotoxin gene of *Bacillus thuringiensis* var. *israelensis*. *Nucleic Acids Res.* 16:1637–1638.
113. Udayasuriyan, V., A. Nakamura, H. Mori, H. Masaki, and T. Uozumi. 1994. Cloning of a new *cryIA(a)* gene from *Bacillus thuringiensis* strain FU-2-7 and analysis of chimeric *cryIA(a)* proteins for toxicity. *Biosci. Biotechnol. Biochem.* 58:830–835.
114. Van Mellaert, H., J. Botterman, J. Van Rie, and H. Joos. January 1991. European Patent EP Office no. 0408403.
115. Visser, B., E. Munsterman, A. Stoker, and W. G. Dirkse. 1990. A novel *Bacillus thuringiensis* gene encoding a *Spodoptera exigua*-specific crystal protein. *J. Bacteriol.* 172:6783–6788.
116. Von Tersch, M. A., and J. M. Gonzalez. October 1994. U.S. patent 5,356,623.
117. Von Tersch, M. A., H. L. Robbins, C. S. Jany, and T. B. Johnson. 1991. Insecticidal toxins from *Bacillus thuringiensis* subsp. *kenyae*: gene cloning and characterization and comparison with *B. thuringiensis* subsp. *kurstaki* CryIA(c) toxins. *Appl. Environ. Microbiol.* 57:349–358.
118. Waalwijk, C., A. M. Dulleman, M. E. S. van Workum, and B. Visser. 1985. Molecular cloning and the nucleotide sequence of the Mr28,000 crystal protein gene of *Bacillus thuringiensis* subsp. *israelensis*. *Nucleic Acids Res.* 13:8207–8217.
119. Wabiko, H., K. C. Raymond, and L. A. Bulla, Jr. 1986. *Bacillus thuringiensis* entomocidal protoxin gene sequence and gene product analysis. *DNA* 5:305–314.
120. Ward, E. S., and D. J. Ellar. 1986. *Bacillus thuringiensis* var. *israelensis* delta-endotoxin: nucleotide sequence and characterization of the transcripts in *Bacillus thuringiensis* and *Escherichia coli*. *J. Mol. Biol.* 191:1–11.
121. Ward, E. S., and D. J. Ellar. 1987. Nucleotide sequence of a *Bacillus thuringiensis* var. *israelensis* gene encoding a 130 kDa delta-endotoxin. *Nucleic Acids Res.* 15:7195.
122. Wasano, N., and M. Ohba. 1998. Unpublished observation.
- 122a. White, J. A., L. J. Maltais, and D. W. Nebert. 1998. An increasingly urgent need for standardized gene nomenclature. See: [http://genetics.nature.com/web\\_specials/nomen/nomen\\_article.html](http://genetics.nature.com/web_specials/nomen/nomen_article.html).
123. Widner, W. R., and H. R. Whiteley. 1989. Two highly related insecticidal crystal proteins of *Bacillus thuringiensis* subsp. *kurstaki* possess different host range specificities. *J. Bacteriol.* 171:965–974.
124. Wu, D., X. L. Cao, Y. Y. Bai, and A. I. Aronson. 1991. Sequence of an operon containing a novel  $\delta$ -endotoxin gene from *Bacillus thuringiensis*. *FEMS Microbiol. Lett.* 81:31–36.
125. Yamamoto, T., I. A. Watkinson, L. Kim, M. V. Sage, R. Stratton, N. Akande, Y. Li, D.-P. Ma, and B. A. Roe. 1988. Nucleotide sequence of the gene coding for a 130-kDa mosquitocidal protein of *Bacillus thuringiensis israelensis*. *Gene* 66:107–120.
126. Zhang, J., T. C. Hodgman, L. Krieger, W. Schnetter, and H. U. Schairer. 1997. Cloning and analysis of the first *cry* gene from *Bacillus popilliae*. *J. Bacteriol.* 179:4336–4341.

*Editor's note: Articles published in this journal represent the opinions of the authors and do not necessarily represent the opinions of ASM.*



42. Porter, N. A. & Weekes, T. C. *Mon. Not. R. astr. Soc.* **183**, 205–210 (1978).
43. Akerlof, C. W. *et al.* in *Proc. 21st ICRC, Adelaide*, vol. 2 (ed. Protheroe, R. J.) 135–138 (Adelaide University, 1990).
44. Porter, N. A. & Weekes, T. C. *Astrophys. J.* **212**, 224–226 (1977).
45. Porter, N. A. & Weekes, T. C. *Mon. Not. R. Astr. Soc.* **183**, 205–210 (1978).
46. Porter, N. A. & Weekes, T. C. *Nature* **277**, 199 (1979).
47. Nolan, K., Porter, N. A., Fegan, D. J., Chantell, M. & Weekes, T. C. *Proc. 21st ICRC, Adelaide*, vol. 2 (ed. Protheroe, R. J.) 150 (Adelaide University, 1990).
48. Fegan, D. J., McBreen, B., O'Brien, D. & O'Sullivan, C. *Nature* **271**, 731–732 (1978).
49. Bhat, P. N. *et al.* *Nature* **284**, 433–434 (1984).
50. Porter, N. A. & Weekes, T. C. *Nature* **267**, 500–501 (1977).

51. O'Mongain, E. *Nature* **242**, 136–137 (1973).
52. Huguenin, G. R. & Moore, E. L. *Astrophys. J.* **187**, L57–L58 (1974).
53. Phinney, S. & Taylor, J. H. *Nature* **277**, 117–118 (1979).
54. Rees, M. J. *Nature* **266**, 333–334 (1977).
55. Jelley, J. V., Baird, G. A. & O'Mongain, E. *Nature* **267**, 499–500 (1977).

ACKNOWLEDGEMENTS. We thank C. J. Goebel for giving his time whenever we needed expert help. We thank N. Porter for discussions. This research was supported in part by the University of Wisconsin Research Committee with funds granted by the Wisconsin Alumni Research Foundation, in part by the US Department of Energy, in part by the Xunta de Galicia (Spain) and in part by the Smithsonian Scholarly Studies Research Fund. J.H.M. is a NAS/NRC research associate.

## ARTICLES

# Crystal structure of insecticidal $\delta$ -endotoxin from *Bacillus thuringiensis* at 2.5 Å resolution

Jade Li\*, Joe Carroll† & David J. Ellar‡

\* Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, UK

† Biochemistry Department, Cambridge University, Tennis Court Road, Cambridge CB2 1QW, UK

The structure of the  $\delta$ -endotoxin from *Bacillus thuringiensis* subsp. *tenebrionis* that is specifically toxic to Coleoptera insects (beetle toxin) has been determined at 2.5 Å resolution. It comprises three domains which are, from the N- to C-termini, a seven-helix bundle, a three-sheet domain, and a  $\beta$  sandwich. The core of the molecule encompassing all the domain interfaces is built from conserved sequence segments of the active  $\delta$ -endotoxins. Therefore the structure represents the general fold of this family of insecticidal proteins. The bundle of long, hydrophobic and amphipathic helices is equipped for pore formation in the insect membrane, and regions of the three-sheet domain are probably responsible for receptor binding.

THE  $\delta$ -endotoxins are a family of insecticidal proteins produced by *Bacillus thuringiensis* (B.t.) during sporulation, having relative molecular masses ( $M_r$ ) 60,000–70,000 (60K–70K) in the active form and specific toxicities against insects in the orders of Lepidoptera, Diptera and Coleoptera<sup>1,2</sup>. These toxins have been formulated into commercial insecticides for three decades<sup>3</sup>, and now insect-resistant plants are engineered by transformation with Lepidoptera-specific toxin genes<sup>4–6</sup>. In the bacterium  $\delta$ -endotoxins are synthesized as protoxins of  $M_r$ s 70K–135K and crystallize as a parasporal inclusion  $\sim 1 \mu$  in size, in which form they are ingested by the susceptible insect. The microcrystal dissolves in the alkaline pH of the midgut and the protoxin is cleaved by gut proteases to release the active toxin.  $\delta$ -Endotoxins activated *in vitro* bind specifically and with high affinity ( $k_D \approx 0.1$ –20 nM) to protein receptors on brush-border membrane vesicles derived from the gut epithelium of target insects<sup>7–9</sup> and create leakage channels of 10–20 Å diameter in the cell membrane<sup>10</sup>. *In vivo* such membrane lesions lead to swelling and lysis of the gut epithelium<sup>11</sup> and death of the insect ensues through starvation and septicaemia. Active  $\delta$ -endotoxins of different specificities show five strongly conserved regions in their amino-acid sequences<sup>1,12</sup>. Exchanging sequence segments in the divergent regions between toxins of different specificities can produce active hybrids showing altered target specificity<sup>13–15</sup>. We have determined the atomic structure of a

Coleoptera-specific  $\delta$ -endotoxin (CryIIIA, beetle toxin) from *B.t.* subsp. *tenebrionis*<sup>16–18</sup> to elucidate the structural basis for target specificity and membrane perforation by this family of proteins.

## Structure determination

Parasporal crystals of the beetle toxin contain the full-length 644-residue protoxin<sup>17</sup> as the minor component, and a product of bacterial processing with 57 residues removed from the N-terminus as the major component<sup>19</sup>. The latter ( $M_r$  67K) is similar in sequence to the active form of other  $\delta$ -endotoxins. After solubilization, papain cleavage converts the mixture to the 67K toxin (see legend to Table 1). This was recrystallized in the original crystal form of the parasporal crystals, space group C222, and cell dimensions 117.1 by 134.2 by 104.5 Å, containing one molecule per asymmetric unit and 55% solvent by volume<sup>18</sup>.

Initial evaluation of derivatives was carried out at 4.5 Å resolution with data collected on the FAST TV diffractometer<sup>20</sup> using CuK $\alpha$  radiation. Complete datasets (Table 1) were then collected to 2.5 Å resolution from native crystals using the imaging plate systems at the EMBL outstation at DESY and from the mercury and platinum derivatives on film at SRS Daresbury. The electron density map (Fig. 1) at 2.5 Å resolution calculated with phases from multiple isomorphous replacement (mean figure of merit, 0.63) was easily interpretable and was improved by solvent flattening<sup>21,22</sup>. A continuous polypeptide chain from residue 61 to residue 644 at the C terminus was traced unambiguously, and most side-chain atoms could be located in the map. The atomic model was built using the graphics program O (ref. 23) and had an initial *R*-factor of 37% for all data to 2.5 Å. After preliminary refinement using the program X-PLOR (ref. 24), the current model, containing 584 amino acid residues and 40 bound water molecules, has an *R*-factor of 19.9% and r.m.s. bond length deviation of 0.017 Å.

## Description of the structure

**Overview.** The beetle toxin is a wedge-shaped molecule with a radius of gyration of 58 Å. As shown in Fig. 2a, it comprises three domains. Domain I, from the N terminus of the 67K toxin to residue 290, is a seven-helix bundle in which a central helix is completely surrounded by six outer helices tilted at about +20° to it (Fig. 3b,c). Domain II, from residues 291 to 500, contains three antiparallel  $\beta$  sheets packed around a hydrophobic core with a triangular cross-section (Fig. 4). Domain III, from residues 501 to 644 at the C terminus is a sandwich of two antiparallel  $\beta$  sheets (Fig. 5). Domains I and III make up the

TABLE 1 Data collection and phasing statistics

Data collection						
Data	Method of collection	Number of crystals	Resolution (Å)	Number of measurements	Unique reflections (% completeness)	$R_{\text{merge}}$
Native	image plate	8	2.5	121,767	27,727 (100)	0.108
CH <sub>3</sub> HgNO <sub>3</sub>	film	7	2.5	103,623	27,767 (100)	0.095
Hg(CH <sub>3</sub> COO) <sub>2</sub>	film	5	2.5	60,224	25,919 (94.5)	0.103
<i>cis</i> -Pt(NH <sub>3</sub> ) <sub>2</sub> Cl <sub>2</sub>	film	7	2.5	86,629	25,924 (94.5)	0.107
K <sub>2</sub> OsO <sub>4</sub>	FAST	1	4.5	21,143	4,680 (100)	0.077
HoCl <sub>3</sub>	FAST	1	4.5	20,013	4,701 (100)	0.069
Phasing statistics						
Derivative	Anomalous data	Number of sites	$R_{\text{deriv}}^{\dagger}$	$R_{\text{Cullis}}^{\ddagger}$	Phasing power§ (resolution, Å)	
CH <sub>3</sub> HgNO <sub>3</sub>	no	3	0.183	0.715	1.56 (2.5)	
Hg(CH <sub>3</sub> COO) <sub>2</sub>	yes	6	0.247	0.609	2.28 (2.5)	
<i>cis</i> -Pt(NH <sub>3</sub> ) <sub>2</sub> Cl <sub>2</sub>	no	5	0.185	0.682	1.54 (2.5)	
K <sub>2</sub> OsO <sub>4</sub>	no	4	0.149	0.757	1.26 (5.5)	
HoCl <sub>3</sub>	no	3	0.095	0.741	1.35 (5.0)	

**Protein preparation:** Solubilized parasporal crystals from *B.t. subsp. tenebrionis* were incubated at 0.5 mg ml<sup>-1</sup> protein with 0.125 units per ml of Agarose-linked papain (Boehringer) in 3.3 M NaBr, 0.05 M sodium phosphate, pH 7.0, and 0.1 mg ml<sup>-1</sup> phenylmethylsulphonylfluoride (PMSF) for 30 min at 20 °C. Digestion was stopped by adding tosyl lysinechloromethylketone (TLCK) to 0.125 mg ml<sup>-1</sup> and Na<sub>2</sub>CO<sub>3</sub> to one fifth volume and removing the enzyme-beads. The 67K beetle toxin was then purified by gel filtration on Sephadex G75 equilibrated with 0.1 M NaHCO<sub>3</sub>, pH 10.5, 0.5 M NaBr. **Crystallization:** Single crystals were obtained by microdialysis at a protein concentration of 2.5 mg ml<sup>-1</sup> against 0.1 M NaHCO<sub>3</sub>, pH 9.5, 1.2 M NaBr at 4 °C overnight, then against 0.1 M NaHCO<sub>3</sub>, pH 9.2, 0.5 M NaBr at 16 °C; 3 mM NaN<sub>3</sub>, 0.1 mM PMSF and 0.1 mg ml<sup>-1</sup> TLCK were present in all buffers. Crystals were transferred by stages to 0.05 M 2-(*N*-morpholino)ethanesulphonic acid (MES), pH 6.5, for derivative preparation and mounted in 0.03% low-melting agarose in this buffer during data collection. **Data collection:** Image plate and film data were processed using MOSFLM (Imperial College, London) and CCP4 programs (Daresbury, UK). FAST (ref. 20) data were collected and processed with MADNES<sup>45</sup>, and scaled in 3° batches. **Derivatives:** Crystals were soaked respectively in 0.25 mM CH<sub>3</sub>HgNO<sub>3</sub> for 3.5 h, in 1 mM Hg(CH<sub>3</sub>COO)<sub>2</sub> for 14 h, in freshly prepared 1 mM *cis*-Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> for 21 h, in saturated K<sub>2</sub>OsO<sub>4</sub> for 35 h, and in 2 mM HoCl<sub>3</sub> for 3 days. **Phase calculation:** Two heavy-atom sites in each derivative were located from difference Patterson functions, except in the case of Hg(CH<sub>3</sub>COO)<sub>2</sub> for which 3 sites were located, and the remaining sites were found by cross-phased difference Fourier. Heavy-atom parameters were refined against centric data and phases calculated for all data using the program PHARE (G. Brice). The two low-resolution derivatives were refined against phases calculated from the high-resolution derivatives. Phasing with the three high-resolution derivatives gave an overall figure of merit of 0.61 (25–2.5 Å) and a clearly interpretable map. Including the remaining derivatives slightly improved the connectivity of the map (overall figure of merit 0.63), and four cycles of solvent flattening using a 50% solvent content and a 9 Å radius in mask calculation<sup>21,22</sup> improved the overall definition of densities. The starting model was built using the program O (ref. 23) with the Bones option for main-chain tracing and the autobuild and manip options for side chains. Refinement by simulated annealing using the program X-PLOR (ref. 24) reduced the *R*-factor from 0.37 to 0.25 without individual *B*-factors, and to 0.23 with restrained individual *B*-factors. The model was adjusted in the loops 154–156, 429–436, and 483–488, and had 40 solvent molecules added, then refined by X-PLOR again. The current model has an *R*-factor of 19.9%, with r.m.s. bond length deviation of 0.017 Å, r.m.s. bond angle deviation of 3.2°, and average atomic *B*-factor of 18 Å<sup>2</sup>.

\*  $R_{\text{merge}} = \sum_i |I_i - \langle I \rangle| / \sum_i \langle I \rangle$ , where  $I_i$  are intensity measurements for a reflection, and  $\langle I \rangle$  is the mean intensity for this reflection.

†  $R_{\text{deriv}} = \sum |F_{\text{PH}} - F_{\text{P}}| / \sum |F_{\text{P}}|$ , where  $F_{\text{PH}}$  is the structure factor amplitude of the derivative crystal and  $F_{\text{P}}$  is that of the native.

‡  $R_{\text{Cullis}} = \sum ||F_{\text{PH}} \pm F_{\text{P}}| - F_{\text{H}}(\text{calc})| / \sum |F_{\text{PH}} - F_{\text{P}}|$ , where  $F_{\text{P}}$  and  $F_{\text{PH}}$  are defined as for  $R_{\text{deriv}}$ , and  $F_{\text{H}}(\text{calc})$  is the calculated heavy-atom structure factor amplitude summed over centric data only.

§ Phasing power =  $(F_{\text{H}})/E$ , the r.m.s. heavy-atom structure factor amplitudes divided by the residual lack of closure error.

bulky end of the molecule. Through their contact one of the two  $\beta$  sheets in domain III is almost entirely buried. To our knowledge (see, for example, ref. 25), the packing of helices in domain I and of sheets in domain II are both novel arrangements.

**Domain I.** The central helix in this seven-helix bundle is  $\alpha_5$  (Fig. 3b,c), which is oriented with its C terminus towards the bulky end of the molecule. Viewed from this end, the outer helices are arranged anticlockwise in the order of  $\alpha_1$ ,  $\alpha_2$ ,  $\alpha_3$ ,  $\alpha_4$ ,  $\alpha_6$  and  $\alpha_7$ , with helices  $\alpha_1$  and  $\alpha_7$  adjacent to the  $\beta$ -sheet domains;  $\alpha_2$  is interrupted by a non-helical section and only the leading half,  $\alpha_{2a}$ , is packed against  $\alpha_5$ . Figure 3a shows the alignment of amino-acid sequence on the surfaces of the helices. The helices are long, especially  $\alpha_3$  to  $\alpha_7$ , which contain respectively 8, 7, 6, 9 and 7 complete helical turns and hence would be long enough to span the 30-Å thick hydrophobic region of a membrane bilayer. Furthermore, the six outer helices bear a strip of hydrophobic residues (defined by  $\Delta G \geq 0$  for transfer from oil to water) down their entire length on the side-facing helix  $\alpha_5$ , so they are amphipathic. In keeping with the general observation that secondary structures are close-packed and bury hydrophobic surfaces<sup>26</sup>, the helix contact angles in this domain cluster around +20° rather than -50°, giving the bundle a bouquet-like appearance (Fig. 3b). Figure 3c shows the bundle in cross-section. The interhelical space contains 27 aromatic residues which are packed in the edge-to-face fashion<sup>27</sup>; all polar groups in this region are hydrogen-bonded or in salt bridges.


The concentric arrangement of the seven-helix bundle is distinct from the two-layered type seen in bacteriorhodopsin. There is some resemblance to the pore-forming domain of colicin A<sup>28</sup>, in which two hydrophobic helices are shielded from solvent by eight amphiphilic helices, but the colicin helices are generally shorter. Like the colicin helices, the bundle in the beetle toxin may be a soluble form of packaging for the hydrophobic and amphiphilic helices that will form pores in the membrane after a large change in conformation.

**Domain II.** In Fig. 4a and 4b the three sheets of this domain are laid side-by-side, as they would be seen from the solvent. There is an apparent structural duplication between the four-stranded antiparallel sheets, sheet 1 and sheet 2. The chain connections,  $\beta_4$ ,  $\beta_3$ ,  $\beta_2$ ,  $\beta_5$  and  $\beta_8$ ,  $\beta_7$ ,  $\beta_6$ ,  $\beta_9$ , respectively, follow the order of +3, -1, -1, +3, which is typical of the 'Greek-key' topology<sup>29</sup>. From both sheets the inner strands,  $\beta_3$  and  $\beta_2$  as well as  $\beta_7$  and  $\beta_6$ , extend some 20 Å to the apex of the molecule as two-stranded  $\beta$  ribbons; and at the point of departure from the sheets there is a  $\beta$ -bulge in  $\beta_3$  and in  $\beta_7$  to twist the plane of the ribbon by nearly 90° relative to the sheet. The connections between the outer strands cross over the ribbons on the solvent side.

The pseudo-symmetry between these sheets is very approximate. Using the least squares option in O (ref. 23), the sheet region of the strands  $\beta_3$  and  $\beta_2$  can be brought to superimpose on that of  $\beta_7$  and  $\beta_6$ , with a r.m.s. fit of 0.72 Å for 13  $\alpha$  carbons. But the r.m.s. fit increased to 1.1 Å for 23  $\alpha$  carbons of the



FIG. 1 Electron density map in the neighbourhood of Cys 243, calculated *a*, using combined phases<sup>46</sup> from multiple isomorphous replacement and solvent flattening, and *b*, using combined experimental and model phases<sup>46</sup> after refinement by X-PLOR. The refined structure is shown superimposed for reference. Although Cys 243 is a major site of both the methylmercury (MM) and mercuric acetate (MA) derivatives, the methyl mercury site is in a hydrophobic environment compared with the mercuric acetate site.



whole inner strands including the ribbon region, and 1.7 Å for 36  $\alpha$  carbons on all four strands. Nonetheless, the sequence alignment brought by this superposition of the two sheets revealed a low level of internal homology, with seven pairs of equivalent residues (shown in bold) out of 41 aligned  $\alpha$  carbons:

```
338 HRIQPHTRPQP(6)SFNYWS(1)NYVSTRPSI(0)GSNDIITSPF(10)NLKFN 395
402 AVANTNLAVWP(0)SAVYSG(1)TKVEFSQYN(3)DEASTQTYDS(7)SWDSI 453
```

The three-stranded sheet 3 is formed by two separate polypeptide segments. The C-terminal segment of domain II contributes the two-stranded ribbon of  $\beta_{10}$  and  $\beta_{11}$ , whereas the N-terminal segment of this domain contributes strand  $\beta_1$ , which is hydrogen-bonded to  $\beta_{11}$ ;  $\beta_1$  is followed by a two-turn helix  $\alpha_8$  and an extended chain.

Figure 4c and d shows in side view and in cross-section that the three antiparallel sheets are packed around a triangular hydrophobic core. This brings the strand  $\beta_{10}$  on the edge of sheet 3 into proximity with strand  $\beta_4$  on the edge of sheet 1, as well as placing the loops at the end of the three  $\beta$  ribbons into a region of about 12 Å radius at the molecular apex. This domain is in contact with helix  $\alpha_7$  of domain I on the face of sheet 3 (Fig. 4c).


**Domain III.** Figure 5 is a ribbon drawing of the strands forming the two sheets of the  $\beta$  sandwich. The sheet containing the C-terminal strand is in contact with domain I and will be called the inner sheet. This domain has the 'jelly-roll' topology<sup>29</sup>, because it can be generated by folding an antiparallel  $\beta$  ribbon which starts with  $\beta_{13}$  (N terminus) and  $\beta_{23}$  (C terminus) on the inner sheet, and ends in the loop between  $\beta_{18}$  and  $\beta_{19}$  on the outer sheet;  $\beta_{14}$  is a short excursion from this ribbon and forms the fifth antiparallel strand of the outer sheet. In addition, small parallel sheets are formed at the edge of the  $\beta$  sandwich through hydrogen bonding of strand  $\beta_{12}$  to  $\beta_{16}$  at the edge of the outer sheet, and  $\beta_1$  to  $\beta_{13}$  at the edge of the inner sheet.

**Distribution of conserved sequences.** The core of the beetle toxin molecule encompassing the domain interfaces is built from the five sequence blocks that are highly conserved throughout the  $\delta$ -endotoxin family<sup>1</sup> (Fig. 2b,c). Block 1, located in the beetle toxin sequence at residues 189–218, corresponds to the central helix ( $\alpha_5$ ) of the bundle in domain I. Block 2, residues 239–305, overlaps with the latter half of  $\alpha_6$ , and with  $\alpha_7$  and  $\beta_1$ ; the latter hydrogen-bonds to the edge of the inner sheet in domain III before forming part of the three-stranded sheet 3 in domain II. Block 3, residues 491–538, overlaps with the latter part of  $\beta_{11}$ , where it is hydrogen-bonded to  $\beta_1$ , and with the loops connecting domains II and III. The remainder of block 3 together with blocks 4 and 5, namely residues 560–569 and 633 to the C terminus, respectively, constitute the three buried strands of the inner antiparallel sheet in domain III. The high degree of conservation of internal residues implies that homologous proteins would adopt a similar fold. Using the beetle toxin structure as a model, we can therefore propose a basis for the insecticidal activity of  $\delta$ -endotoxins as a family.

### Basis of insecticidal function

**Solubility.** The beetle toxin crystals are isomorphous with the parasporal crystals<sup>18,19</sup> and show the molecular contacts responsible for solubility behaviour *in vivo*. Four intermolecular salt bridges, Asp 142–Arg 165, Asp 224–Arg 562, Asp 590–Arg 178, and Glu 223–Lys 293, are located at contacts to three different neighbouring molecules. Such salt bridges keep the protoxin crystals insoluble until exposed to the extreme pHs in the insect midgut.

**Proteolytic activation.** Pro- $\delta$ -endotoxins have  $M_s$  of either ~130K or ~70K. Activation by larval gut proteases removes the C-terminal half of the larger protoxins<sup>30,31</sup> and cleaves them at residue 28 or 29 from the N terminus. The smaller protoxins, such as that of the beetle toxin, are processed only at the N






FIG. 3 The seven-helix bundle. *a*, Helical nets showing the position of amino-acid residues along the 7 helices:  $\alpha_1$  (63-79);  $\alpha_2$  ( $\alpha_{2a}$ , 85-98 and  $\alpha_{2b}$ , 104-117);  $\alpha_3$  (123-152);  $\alpha_4$  (160-185);  $\alpha_5$  (193-214);  $\alpha_6$  (222-254) and  $\alpha_7$  (259-285). The cylindrical surface of the helices are cut longitudinally on the side facing the solvent and flattened to give a view from the interior of the bundle. The top of the drawing corresponds to the bulky end of the whole molecule. Owing to tilting of the outer helices, different helices are in register vertically only at a level indicated by two arrows pointed at  $\alpha_1$  and  $\alpha_7$ ;  $\alpha_5$  is the central helix. Dotted curves outline the strip of hydrophobic residues down the inward surface of the other six helices. *b*,  $C\alpha$  trace (stereoview) for the bundle viewed perpendicular to  $\alpha_5$ . The relative tilt of the outer helices to  $\alpha_5$  and that between adjacent outer helices are both about  $20^\circ$ . The  $C\alpha$  trace is shaded grey over helices  $\alpha_1$  to  $\alpha_3$  in the back, striped over helix  $\alpha_5$  in the centre, and white over helices  $\alpha_4$ ,  $\alpha_5$ , and  $\alpha_7$  in the front. *c*, Cross-section of the bundle at the level indicated by the arrows in *a*, viewed from the bulky end of the molecule. The helical backbone is represented by curly ribbons passing through the  $C\alpha$  positions. The outer helices are positioned roughly hexagonally around the central one and tilted relative to it, so the bundle forms a left-handed superhelix. The aromatic side chains are packed in an edge-to-face fashion. Hydrogen bonds are shown for side-chain atoms.

terminus<sup>19,32</sup> where about 50 residues are removed. The activated  $\delta$ -endotoxins show a conserved C-terminus, so-called sequence block 5 (ref. 1). Its position as the middle strand of the buried  $\beta$  sheet in domain III precludes further processing from the C terminus. In fact deletion from this site by 4 to 8 residues results in inactive mutants with altered solubility and immunogenicity<sup>30,33-35</sup>. This is not surprising as the inner sheet can be expected to play a critical part in the structural integrity and stability of the toxins through interaction with the helical bundle.

At the N-terminal cleavage sites the different protoxin sequences show locally similar hydropathy profiles<sup>36,37</sup>, which would be consistent with a common topology for the N-terminal region of the activated toxins as seen in the helical bundle of

the beetle toxin. In crystals of the beetle toxin, the N terminus at the start of helix  $\alpha_1$  borders on a large solvent channel of about 30 Å diameter that crosses the unit cell along the *c* direction (Fig. 2*d*). This channel could allow access of sporulation-associated proteases to the cleavage site in parasporal crystals<sup>19</sup>.

**Receptor binding.** The insecticidal selectivity of  $\delta$ -endotoxins is due to high-affinity binding to specific membrane receptors<sup>7-9,38</sup>, which in three cases seem to be glycoproteins<sup>38-40</sup>. For several  $\delta$ -endotoxins the specificity-determining regions have been delimited by exchanging sequence segments between closely related toxins of differing specificities<sup>13-15</sup>. Guided by the location of secondary structures in the beetle toxin, a plausible alignment of  $\delta$ -endotoxin sequences was made for the non-




FIG. 4 The three sheets of domain II. *a*, Schematic ribbon drawing of sheets 1, 2, and 3 laid side-by-side. Each is viewed from the exterior of the domain. Note the Greek-key topology of sheets 1 and 2 and the similarity between their fold. *b*, Hydrogen bonding of the polypeptide backbone for the three sheets. The  $\beta$  strands are shown by the main-chain atoms and by the residue numbers at their ends; connecting strands are shown as coils. *c*,  $C\alpha$  trace of the three assembled sheets in domain II viewed towards domain I (stereoview). The  $C\alpha$  trace is shaded grey over sheet I, striped over sheet II, and white over sheet III. *d*, Cross-section of domain II (stereoview) showing the packing of three sheets in a triangle around the hydrophobic core. The view is towards domain III.

conserved regions (ref. 12, and T. C. Hodgman, unpublished results). Hence the genetically identified specificity-determining regions can be mapped to equivalent positions in the beetle toxin structure, and these fall mainly in domain II. For instance, the dual specificity of CryIIA for Lepidoptera and Diptera, as distinct from the Lepidoptera specificity in the closely related CryIIB, is determined by residues 307–382 of their sequences<sup>14</sup>, which corresponds roughly to sheet 1 (Fig. 4a) plus strand  $\beta_6$  in sheet 2 and the loop leading up to  $\beta_7$ , whereas the Lepidoptera

specificity of CryIIB is dependent on a longer segment<sup>14</sup> that would include both inner strands of sheet 2. Similarly, the toxicities of CryIA(a) and CryIA(c) to two lepidopteran insects depend on three segments termed x, y and z (ref. 15): amino-acid substitutions in y can reduce toxicity by up to 2,000-fold, and segments x and y interact in determining specificity. Aligned with the beetle toxin structure, segment x corresponds roughly to the outer strands  $\beta_4$  and  $\beta_5$  of sheet 1 and the whole of sheet 2, including the loop entering  $\beta_{10}$  in sheet 3; y corresponds to




FIG. 5 Domain III, schematic ribbon representation of the  $\beta$  sandwich.  $\beta$  strands forming the inner sheet are shaded grey. The topology of an eight-stranded 'jelly-roll' can be seen by following the  $\beta$  hairpin starting with  $\beta_{13}$ ,  $\beta_{15}$  and  $\beta_{23}$  in the inner sheet, continuing to  $\beta_{16}$  and  $\beta_{22}$  in the outer sheet, then  $\beta_{17}$  and  $\beta_{21}$ ,  $\beta_{20}$  in the inner sheet, and ending with  $\beta_{18}$  and  $\beta_{19}$  in the outer sheet.  $\beta_{14}$  is an excursion from the hairpin and forms a fifth antiparallel strand of the outer sheet. Small parallel  $\beta$  sheets are added to one edge of the  $\beta$  sandwich, by hydrogen bonding of  $\beta_1$  to  $\beta_{13}$  in the inner sheet and  $\beta_{12}$  to  $\beta_{16}$  in the outer sheet. Residue numbers in the  $\beta$  strands are:  $\beta_{12}$ , 502–506;  $\beta_{13}$ , 509–513;  $\beta_{14}$ , 519–525;  $\beta_{15}$ , 536–541;  $\beta_{16}$ , 547–554;  $\beta_{17}$ , 558–569;  $\beta_{18}$ , 573–579;  $\beta_{19}$ , 585–591;  $\beta_{20}$ , 604–609;  $\beta_{21}$ , 611–614;  $\beta_{22}$ , 619–625; and  $\beta_{23}$ , 631–643.

strand  $\beta_{10}$  of sheet 3 and the loop connecting  $\beta_{10}$  and  $\beta_{11}$ ; and  $z$  extends from  $\beta_{11}$  to the C-terminal activation site. Furthermore, the interaction between  $x$  and  $y$  can be understood in terms of the proximity between  $\beta_4$  on the edge of sheet 1 and  $\beta_{10}$  on the

edge of sheet 3. Although  $z$  was inferred<sup>15</sup> to extend into domain III, the combined evidence from genetics and receptor-binding assays *in vitro* for Lepidoptera toxins<sup>9,41</sup> correlates receptor recognition with sequence variations within domain II. We note that the  $\beta$  ribbons from all three sheets terminate in loops in a small region on the molecular apex, in a manner reminiscent of the complementarity-determining region of immunoglobulins.

**Pore formation.** The common mechanism of epithelial cell disruption by  $\delta$ -endotoxins of widely different specificities is believed to be the formation of lytic pores of 10 to 20 Å diameter in the insect membrane<sup>10</sup>. The structure of the beetle toxin displays an apparatus for pore formation in the long, hydrophobic and amphipathic helices of domain I which could penetrate the membrane. Between the crystal structure in which the bouquet-like helical bundle internalizes all the hydrophobic surfaces, and the unknown pore structure where hydrophobic surfaces would be in intimate contact with the membrane lipids, large conformational changes must occur. In the absence of a full characterization of the pore-forming process, we propose the following by extrapolation from the crystal structure.

The trigger for the conformational changes may be provided by receptor binding and the consequent interaction of toxin with the membrane bilayer. Membrane insertion follows rapidly, so that a major part of the bound  $\delta$ -endotoxin cannot be displaced from the brush-border vesicles by other toxins recognizing the same receptor sites<sup>7,9</sup>. As domain II and probably its apical region are most likely to bind the membrane receptors, the helices are expected to insert with the 'domain II end' (see Fig. 2a) oriented towards the cytoplasm. If helical hairpins are to initiate the membrane penetration, as probably happens for colicin<sup>28,42,43</sup>, they will probably be linked at the domain II end. So either of the helix pairs  $\alpha_6$ – $\alpha_7$  or  $\alpha_4$ – $\alpha_5$  could be the likely initiator. The  $\alpha_6$ – $\alpha_7$  pair is favoured because it forms part of the conserved interface with domain II and is well positioned to sense the receptor binding. On the other hand, helix  $\alpha_5$  is the most conserved throughout the family of  $\delta$ -endotoxins. Point mutations in  $\alpha_5$  reduce toxicity of a Lepidoptera toxin without reducing binding to membranes<sup>44</sup>. Proteolysis in the interhelical loops at the domain III end, as in the  $\alpha_3$ – $\alpha_4$  loop<sup>19,32</sup>, may facilitate release of the helix pairs from the tertiary structure of the bundle. The insertion of a hairpin can create a defect in the membrane, allowing the rest of domain I to participate in pore formation in a cooperative manner. □

Received 22 July; accepted 19 September 1991.

- Höfte, H. & Whiteley, H. R. *Microbiol. Rev.* **53**, 242–255 (1989).
- Ellar, D. J. *et al.* In *Molecular Biology of Microbial Differentiation* (eds Hoch, J. A. & Setlow, P.) 230–240 (Am. Soc. Microbiol., Washington, DC, 1985).
- Wilcox, E. R. *et al.* In *Protein Engineering: Applications in Science, Medicine and Industry* (eds Inoué, M. & Sarma, R.) 395–413 (Academic, New York, 1986).
- Vaeck, M. *et al.* *Nature* **328**, 33–37 (1987).
- Perlak, F. J., Fuchs, R. L., Dean, D. A., McPherson, D. L. & Fischhoff, D. A. *Proc. natn. Acad. Sci. U.S.A.* **88**, 3324–3328 (1991).
- Barton, K. A., Whiteley, H. R. & Yang, N. S. *Plant Physiol.* **85**, 1103–1109 (1987).
- Hofmann, C., Lüthy, P., Hütter, R. & Pliska, V. *Eur. J. Biochem.* **173**, 85–91 (1988).
- Hofmann, C. *et al.* *Proc. natn. Acad. Sci. U.S.A.* **85**, 7844–7848 (1988).
- Van Rie, J., Jansens, S., Höfte, H., Degheete, D. & Van Mellaert, H. *Appl. Envir. Microbiol.* **58**, 1378–1385 (1990).
- Knowles, B. H. & Ellar, D. J. *Biochim. biophys. Acta* **924**, 509–518 (1987).
- Endo, Y. & Nishitsutsuji-Uwo, J. *J. Invertebr. Path.* **36**, 90–103 (1980).
- Hodgman, T. C. & Ellar, D. J. *J. DNA Sequ. Map.* **1**, 97–106 (1990).
- Ge, A. Z., Shivarova, N. I. & Dean, D. H. *Proc. natn. Acad. Sci. U.S.A.* **88**, 4037–4041 (1989).
- Widner, W. R. & Whiteley, H. R. *J. Bact.* **172**, 2826–2832 (1990).
- Schnepf, H. E., Tomczak, K., Ortega, J. P. & Whiteley, H. R. *J. biol. Chem.* **265**, 20923–20939 (1990).
- Krieg, A., Huger, A. M., Langenbruch, G. A. & Schnetter, W. *J. appl. Entomol.* **96**, 500–508 (1983).
- Höfte, H., Seurinck, J., Van Houtven, A. & Vaeck, M. *Nucleic Acids Res.* **15**, 7183 (1987).
- Li, J., Henderson, R., Carroll, J. & Ellar, D. J. *J. molec. Biol.* **199**, 543–545 (1988).
- Carroll, J., Li, J. & Ellar, D. J. *Biochem. J.* **261**, 99–105 (1989).
- Arndt, U. W. *Meth. Enzym.* **114**, 472–485 (1985).
- Wang, B. C. *Meth. Enzym.* **115**, 90–112 (1985).
- Leslie, A. G. W. *Acta crystallogr.* **A43**, 134–136 (1987).
- Jones, T. A., Zou, J.-Y., Cowan, S. W. & Kjeldgaard, N. *Acta crystallogr.* **A47**, 110–119 (1991).
- Brünger, A. T. *J. molec. Biol.* **203**, 803–816 (1988).
- Chothia, C. & Finkelstein, A. V. *Rev. Biochem.* **59**, 1007–1039 (1990).

- Chothia, C. *J. molec. Biol.* **105**, 1–15 (1976).
- Burley, S. K. & Petsko, G. A. *Science* **229**, 23–28 (1985).
- Parker, M. W., Pattus, F., Tucker, A. D. & Tsernoglou, D. *Nature* **337**, 93–96 (1989).
- Richardson, J. S. *Adv. Prot. Chem.* **34**, 167–339 (1981).
- Höfte, H. *et al.* *Eur. J. Biochem.* **161**, 273–280 (1986).
- Choma, C. T. & Kaplan, H. *Biochemistry* **29**, 10971–10977 (1990).
- Nicholls, C. N., Ahmad, W. & Ellar, D. J. *J. Bact.* **171**, 5141–5147 (1989).
- MacIntosh, S. C., McPherson, S. L., Perlak, F. J., Marrone, P. G. & Fuchs, R. L. *Biochem. biophys. Res. Commun.* **170**, 665–672 (1990).
- Schnepf, H. E. & Whiteley, H. R. *J. biol. Chem.* **260**, 6273–6280 (1985).
- Adang, M. J. *et al.* *Gene* **36**, 289–300 (1985).
- Sekar, R., Thompson, D. V., Maroney, M. J., Bookland, R. G. & Adang, M. J. *Proc. natn. Acad. Sci. U.S.A.* **84**, 7036–7040 (1987).
- Chungiatupornchai, W., Höfte, H., Seurinck, J., Angsuthanasombat, C. & Vaeck, M. *Eur. J. Biochem.* **173**, 9–16 (1988).
- Knowles, B. H., Thomas, W. E. & Ellar, D. J. *FEBS Lett.* **168**, 197–202 (1984).
- Knowles, B. H. & Ellar, D. J. *J. Cell Sci.* **83**, 89–101 (1986).
- Haider, M. Z. & Ellar, D. J. *Biochem. J.* **248**, 197–201 (1987).
- Visser, B., Munsterman, E., Stoker, A. & Dirske, W. G. *J. Bact.* **172**, 6783–6788 (1990).
- Lakey, J. H., Baty, D. & Pattus, F. *J. molec. Biol.* **218**, 639–653 (1991).
- Song, H. Y., Cohen, F. S. & Cramer, W. A. *J. Bact.* **173**, 2927–2934 (1991).
- Ahmad, W. & Ellar, D. J. *FEMS Microbiol. Lett.* **68**, 97–104 (1990).
- Messerschmidt, A. & Plüger, J. W. *J. appl. Crystallogr.* **20**, 306–315 (1987).
- Read, R. J. *Acta crystallogr.* **A42**, 140–149 (1986).
- Kraulis, P. J. *J. appl. Crystallogr.* (in the press).

**ACKNOWLEDGEMENTS.** We thank P. R. Evans, A. G. W. Leslie and R. Henderson for advice and encouragement; K. Wilson and Z. Dauter for help with the image plate system; K. Nagai and P. J. McLaughlin for help in collecting film data; T. A. Jones for advice on model building; SERC Daresbury Laboratory and EMBL Outstation at DESY for use of synchrotron facilities; and T. Woolfard and K. Hopkins for maintaining the rotating anodes. D.J.E. and J.C. acknowledge the support of the AFRC

# Structure of Cry2Aa Suggests an Unexpected Receptor Binding Epitope

R.J. Morse,<sup>1</sup> T. Yamamoto,<sup>2,4</sup> and R.M. Stroud<sup>1,3</sup>

<sup>1</sup>Department of Biochemistry and Biophysics  
University of California, San Francisco  
San Francisco, California 94143

<sup>2</sup>Sandoz Agro  
975 California Avenue  
Palo Alto, California 94304

## Summary

**Background:** Genetically modified (GM) crops that express insecticidal protein toxins are an integral part of modern agriculture. Proteins produced by *Bacillus thuringiensis* (Bt) during sporulation mediate the pathogenicity of Bt toward a spectrum of insect larvae whose breadth depends upon the Bt strain. These transmembrane channel-forming toxins are stored in Bt as crystalline inclusions called Cry proteins. These proteins are the active agents used in the majority of biorational pesticides and insect-resistant transgenic crops. Though Bt toxins are promising as a crop protection alternative and are ecologically friendlier than synthetic organic pesticides, resistance to Bt toxins by insects is recognized as a potential limitation to their application.

**Results:** We have determined the 2.2 Å crystal structure of the Cry2Aa protoxin by multiple isomorphous replacement. This is the first crystal structure of a Cry toxin specific to Diptera (mosquitoes and flies) and the first structure of a Cry toxin with high activity against larvae from two insect orders, Lepidoptera (moths and butterflies) and Diptera. Cry2Aa also provides the first structure of the proregion of a Cry toxin that is cleaved to generate the membrane-active toxin in the larval gut.

**Conclusions:** The crystal structure of Cry2Aa reported here, together with chimeric-scanning and domain-swapping mutagenesis, defines the putative receptor binding epitope on the toxin and so may allow for alteration of specificity to combat resistance or to minimize collateral effects on nontarget species. The putative receptor binding epitope of Cry2Aa identified in this study differs from that inferred from previous structural studies of other Cry toxins.

## Introduction

The almost 20 million hectares of GM crop fields in North America consist of crops engineered for herbicide or insect resistance. The genes that confer the latter trait come from *Bacillus thuringiensis* (Bt), a family of Gram-positive sporulating soil bacteria that produce parasporal crystals with insecticidal activity. The insecticidal activity of particular Bt isolates is directed against narrow spectra of insect larval species, usually within a

single order. Bacterial toxins known as insecticidal crystal proteins (ICPs) or crystalline (Cry) proteins that are sequestered as protoxins in crystalline inclusions after sporulation mediate this species-specific pathogenicity [1]. The Cry protoxins are ingested, solubilized in the larval gut [2, 3], and activated by the removal of an amino-terminal segment and a C-terminal segment, the size of which depends on the gene or its protoxin [2, 4]. The active toxins associate with insect-specific receptors of gut epithelial cells of the target insect [5] and subsequently insert into the cell membrane [6, 7], leading to the formation of ion channels [8, 9, 10]. This results in disruption of the electrochemical balance across the basal membrane, gut paralysis, and larval death [11, 12, 13, 14]. The host cadaver serves as growth medium for vegetative cells arising from germination of the Bt endospores.

Species selectivity of Cry proteins is encoded in the binding site for the target receptor [5]. Classification of the Cry proteins is based on amino acid sequence identity [15] and is roughly correlated with the taxonomic order of susceptible insect species, spanning species of agricultural (Cry1 Lepidoptera, Cry2 Lepidoptera, and Cry3 Coleoptera) and public health (Cry2 and Cry4 Diptera) significance. The structure may help guide mutagenesis followed by screening that is directed toward the fine tuning of species selectivity in order to design insecticides that do not kill nontarget organisms such as monarch larvae [16]. It also may assist in the elucidation of the structural basis of resistance to Bt toxins and the subsequent generation of novel insecticidal toxins for use on Bt-resistant insects [17, 18].

Structure-based protein engineering of Cry toxins may direct the search for variants with broader susceptible species spectra, optimal potency, and stability properties. Cry2Aa is among an unusual subset of Cry proteins possessing broad insect species specificity by exhibiting high specific activity against two insect orders, Lepidoptera and Diptera [19, 20]. It is lethal to more lepidopteran species than the Cry1 toxins deployed against agriculturally important Lepidoptera [21] and exhibits a low level of crossresistance in Cry1A-resistant insects [22]. Also, the mode of action of Cry2Aa may be distinct from that of other Cry toxins [23]. Thus, it could serve as a platform for the design of Cry toxins with broader susceptible species spectra and minimal Cry1A-derived crossresistance in the field.

Chimeric-scanning mutagenesis experiments have identified disjoint blocks (D and L, see Results and Discussion) of the Cry2Aa sequence that separately confer specificity against dipteran (D) and lepidopteran (L) species [24, 25]. These experiments also demonstrate that maximal activity against lepidopteran species requires not only L block residues but also some of the specificity determinants of the D residue block. Further, Cry2Ab, an 87% sequence identical homolog of Cry2Aa, has

<sup>3</sup>Correspondence: stroud@msg.ucsf.edu

<sup>4</sup>Present address: Maxisgen, Redwood City, California, 94063.

**Key words:** *Bacillus thuringiensis*; delta-endotoxin; Cry2Aa; binding epitope; crystal structure; X-ray



Table 1. Data Collection, MIR Phasing, and Structure Refinement Statistics for Cry2Aa

	Native	U(NO <sub>3</sub> )	PtCNS	PtI <sub>6</sub>	NbCl <sub>5</sub>	Ru <sup>1</sup>	Hg <sup>2</sup>
Data Collection (1.08 Å)							
Resolution (Å)	2.2	2.6	2.5	2.6	2.6	2.5	2.5
Unit cell dimensions (Å)	a = b = 85.6 c = 163.9						
Space group	P4 <sub>3</sub> 2 <sub>1</sub> 2						
Number of observed reflections ( $\sigma_F - 2.5$ )	245,580	69,703	139,057	70,618	73,949	113,242	126,930
Number of unique reflections	31,591	17,370	20,476	17,999	17,455	19,475	20,198
Completeness (%)	99.3	89.1	99.0	92.	89.3	94.7	97.0
R <sub>merge</sub> (%)	5.7	5.1	5.7	4.7	4.3	5.4	6.3
Phasing/MIR							
Resolution		2.6	2.6	2.6	4.5	2.6	5.25
Number of sites refined		5	6	7	6	5	3
Number of reflections ( $\sigma_F$ 3)		16,177	17,808	16,516	3,136	17,074	2,419
R <sub>iso</sub> (%)		16	24	32	10	10	16
R <sub>cutis</sub>		.62	.62	.59	.60	.67	.62
R <sub>trout</sub>		.13	.15	.20	.06	.08	.09
Phasing power		1.1	1.9	1.8	1.4	0.8	1.2
<FOM> <sub>centric</sub> <sup>3</sup>		.36	.39	.41	.41	.30	.42
<FOM> <sub>overall</sub> ( $n_{\text{phased}}$ ) <sup>4</sup>	.65 (18,677)						
Refinement							
Resolution (Å)	28.0–2.2						
Number of reflections (completeness %)	31,509 (93)						
R <sub>cryst</sub> [ $\sigma_F = 0$ ] (2.3–2.2 Å)	.18 (.21)						
R <sub>free</sub> [5% test] (2.3–2.2 Å)	.24 (.23)						
Number of non hydrogen atoms	5,001						
Number of water molecules	514						
Rms bond distances (Å)	.005						
Rms bond angles (°)	1.2						

<sup>1</sup> [Ru(NH<sub>3</sub>)<sub>6</sub>]Cl<sub>3</sub>.<sup>2</sup> Para chloromercuri phenol (PCMP).<sup>3</sup> Individual data set results.<sup>4</sup> Final number of phased reflections.

negligible activity against dipteran species and 3- to 8-fold less activity against certain lepidopteran species [25, 26]. Hence, Cry2Aa structure and mutagenesis data provide the basis for future protein engineering of Cry toxins with modified specificity and selectivity profiles.

To understand the structural determinants of Cry toxin specificity, we determined the crystal structure of the protoxin of Cry2Aa from *Bacillus thuringiensis* subsp. *kurstaki*. The complete structure was determined by multiple isomorphous replacement and refined to 2.2 Å resolution. We have identified a candidate toxin receptor binding surface that is consistent with available chimeric-scanning mutagenesis data.

## Results and Discussion

The structure of Cry2Aa from *Bacillus thuringiensis* subsp. *kurstaki* was determined by multiple isomorphous replacement using six heavy atom derivatives and was refined to 2.2 Å resolution with R<sub>cryst</sub> = 18% (Table 1). The structure of the 633-amino acid protoxin contains the N-terminal 49-amino acid peptide that is cleaved upon activation and the three domains of what will become the mature toxin [27]. The structures of the three domains are surprisingly similar in overall topology (Figure 1a) to those of the activated toxins Cry3Aa [28] and Cry1Aa [29], suggesting that removal of the activa-

tion peptide serves to expose regions of the toxin rather than alter its conformation. This structural homology is also surprising since these toxins have little sequence identity to Cry2Aa (20% and 17%, respectively). In the mature toxin, the N-terminal domain (residues 1–272) is a pore-forming seven-helical bundle (Figure 1d) [1]. The second domain (residues 273–473) is a receptor binding  $\beta$  prism, a three-fold symmetric arrangement of  $\beta$  sheets, each with a Greek key fold (Figure 1e). The third domain (residues 474–633) is implicated in determining both larval receptor binding [30, 31] and pore function [32] and is a lectin-like C-terminal  $\beta$  sandwich (Figure 1f).

Available chimeric-scanning mutagenesis data [24, 25] define a candidate toxin-receptor binding surface on Cry2Aa that is comprised of a distribution of hydrophobic residues (Ile474–Ala477 from  $\beta$ 12a, Val365–Leu369 from the  $\beta$ 5– $\beta$ 6 loop, and Leu402–Leu404 from the  $\beta$ 7– $\beta$ 8 loop) across the solvent-exposed surface of the  $\beta$  prism and  $\beta$  sandwich domains (Figure 1b). Proteolytic activation of the toxin involves the removal of the 49 N-terminal amino acids and exposes residues comprising this putative toxin-receptor binding surface. Removal of the 49 amino terminal residues, comprised of  $\alpha$ 0,  $\alpha$ 0a, and an N-terminal coil, would not affect the structure of the seven-helical membrane insertion domain, as seen by comparing the structures of the activated toxin Cry1Aa and that of the protoxin Cry2Aa.




Figure 1. Topology and Solvent Accessible Surface of Cry2Aa

(a) Ribbon diagram, rendered by Midas Plus [48], of Cry2Aa. Domain I is shown in magenta, domain II is shown in blue, and domain III is shown in cyan. The N terminus is shown in red, while functionally important loops delimiting the putative toxin-receptor binding epitope are shown in green. A Cry2Aa insertion, relative to Cry3Aa and Cry1Aa, before  $\beta 12$  at the N terminus of domain III is shown in magenta. Numbered  $\beta$  strands referred to in the text are labeled.

(b) The solvent accessible surface, as calculated by GRASP [49], of domains II and III of Cry2Aa. The orientation is identical to that shown in Figure 1a. The projection of residue hydrophobicity onto this surface is shown in color. Portions of the hydrophobic surface contributed by residues 474, 476, and 477 are shown in cyan, those contributed by residues 365-369 are shown in blue, those contributed by residues 402 and 404 are shown in magenta, and the remainder of the surface contributed by hydrophobic residues is shown in yellow. The remaining surface that is identified as nonhydrophobic is colored white. Residue hydrophobicity is as defined by GRASP [49].

The prominent hydrophobic patch is the center of the putative toxin-receptor binding epitope. For orientation, the portion of the surface contributed by residue 357 of the  $\beta 4$ - $\beta 5$  loop is shown in red.

(c) The solvent accessible surface (as calculated by GRASP) of domains II and III of Cry2Aa. The orientation is identical to that shown in Figure 1a. The projection of residue hydrophobicity onto this surface is shown in yellow, while the N terminus is shown in red; the N terminus sterically hinders access to the putative toxin-receptor binding epitope. Portions of the surface that are identified as nonhydrophobic are colored white.

(d-f) The three domains of Cry2Aa shown in the same orientation as in Figure 1a. Labels with amino acid numbers identify the visible N and C termini of each domain in the figures.

This is also expected since constructs consisting of the N-terminal-helical domain of the complete Cry3Ba1 protoxin (prior to cleavage) are capable of nonreceptor-mediated partitioning into lipid bilayers [33], as is the activated toxin.


The structure of Cry2Aa suggests that the N-terminal residues should sterically hinder access to the putative binding epitope  $\beta 5$ - $\beta 6$  and  $\beta 7$ - $\beta 8$  loops (Figure 1a, shown in green) and the exposed parts of domain III closest to domain II. Projection of hydrophobicity onto the solvent accessible surface of domains II and III reveals an  $800 \text{ \AA}^2$  hydrophobic patch (Figure 1b) proximal to these loops. However, while the structure suggests that the 49 N-terminal residues ( $\alpha 0$ ,  $\alpha 0a$ , and the N-terminal coil) should sterically hinder access to the putative binding epitope, the biological rationale for this function is unclear. It is unlikely that Bt possesses a receptor with affinity for the activated toxin. Hence, it does not seem likely that the N terminus serves to prevent premature activation of the toxin within Bt. One simple explanation is that occlusion of the hydrophobic patch of the putative binding epitope prevents nonspecific aggregation of the toxin with itself or other host proteins. Another explanation is that the N-terminal amino acids play a role in the formation of the environmentally stable crystalline inclusions.

The specificity-distinguishing residues are also indicated by comparison of the Cry2Aa structure with the structure of the highly homologous (87% sequence identity) Cry2Ab that is inactive against some Cry2Aa target

species (Figure 2a). Chimeric-scanning mutagenesis [24, 25] defines a continuous 106 amino acid block, 307-412, of specificity-distinguishing residues. (Specifically, [25] demonstrated that substitution of residues 278-340 resulted in loss of dipteran-specific activity in Cry2Aa, while [24] demonstrated that substitution of residues 307-382 conferred dipteran-specific activity to Cry2Ab. Thus, in our discussion, we adopt residue 307 as the N-terminal boundary of the specificity-conferring sequence in Cry2Aa.) Within these 106 amino acids, there are 23 residues that differ between Cry2Aa and Cry2Ab (sequence alignment presented in Figure 5). Most of the Cry2Aa-Cry2Ab amino acid differences lie within or about the domain II/III  $800 \text{ \AA}^2$  hydrophobic patch (Figure 1b) and surrounding residues from the  $\beta 5$ - $\beta 6$ ,  $\beta 7$ - $\beta 8$ , and  $\beta 4$ - $\beta 5$  loops (Figure 1a). The picture of the putative toxin-receptor binding surface that emerges is that of an  $800 \text{ \AA}^2$  hydrophobic region surrounded by three loops, those joining  $\beta 4$ - $\beta 5$ ,  $\beta 5$ - $\beta 6$ , and  $\beta 7$ - $\beta 8$ , which are also a part of the putative binding site. The three loops contain hydrophilic side chains that may be involved in specific hydrogen bonding with the receptor and so signal a portion of the site that could be mutated both to probe these interactions and to alter specificity.

The proximity of this surface to solvent-exposed loops of the lectin-like domain III is consistent with the finding that domain III plays a role in the fine tuning susceptibility of different species. This has been demonstrated by replacement of domain III [30, 31] to make chimeric toxins with altered specificity characteristics. The N-ter-





**Figure 2. Space-Filling Representation of Cry2Aa Specificity-Confering Residues, Detail of Buried D Block Residues, and Electron Density Covering Buried D Block Residues**

(a) Space-filling model of Cry2Aa domains II and III with the N terminus and membrane-inserting domain I removed. The orientation reflects a  $-20^\circ$  rotation relative to that shown in Figure 1a. The results of chimeric-scanning [24, 25] mutagenesis experiments are projected onto the van der Waals surface of Cry2Aa. The residues colored green and cyan are single amino acid differences between Cry2Aa and Cry2Ab in block L (residues 341–412). The residues colored yellow and orange are single amino acid differences between Cry2Aa and Cry2Ab in block D (residues 307–340). The bar represents an approximate 10 Å scale.

(b) Packing of D block residues behind the  $\beta 4$ - $\beta 5$  loop. The  $\beta 4$ - $\beta 5$  loop contains L block specificity determinants with which the buried D block residues interact.

(c) Electron density for the putative receptor binding site covering residues of the  $\beta$  sheet behind the  $\beta 4$ - $\beta 5$  loop.


minimal strand  $\beta 12a$  of domain III is not present in the three-dimensional structures of Cry1Aa or Cry3Aa. The turn between this strand and the rest of domain III is functionally replaced almost exactly by a loop that connects  $\beta 3$  and  $\beta 4$  of domain II in the homologous Cry1Aa and Cry3Aa structures (Figures 1a and 3, shown in ma-

genta). This functionally conserved  $\beta 12a$  motif occupies the same region of the structure as the  $\beta 3$ - $\beta 4$  turn in Cry1Aa and Cry3Aa, so it implies conservation of a functional role in protecting the hydrophobic portion of the putative receptor binding surface implicated by the homolog substitutions.

Chimeric-scanning mutagenesis identifies fairly large



**Figure 3. Detail of Ribbon Diagram Overlap of Cry2Aa and Cry1Aa**  
The Cry1Aa domains have been independently fit to those of Cry2Aa. The functionally important loops delimiting the putative toxin-receptor binding epitope are shown in green (Cry2Aa) and blue (Cry1Aa). The Cry2Aa insertion, relative to Cry3Aa and Cry1Aa, before  $\beta 12$  at the N terminus of domain III is shown in magenta, while the corresponding loop from Cry1Aa is shown in cyan (see arrow).



**Figure 4. Schematic Representation of Chimeric-Scanning Mutagenesis Data**

The first and last bands represent the Cry2Aa and Cry2Ab sequences, respectively. The middle bands represent chimeric combinations in which gray regions correspond to Cry2Ab sequence and white regions correspond to Cry2Aa sequence. For all bands, except that corresponding to Hyb513, the three central vertical bars represent amino acids 278, 340, and 412. For Hyb513, the two central vertical bars represent amino acids 307 and 382. The activity designations represent an approximate log scale. For example, the (++++) activity designation for chimera DL112 corresponds to an  $ID_{50}$  of 126 (85.7–187) ng, while the (+) designation for chimera DL115 corresponds to an  $ID_{50}$  of 3,200 (1,340–51,900) ng; the confidence intervals correspond to  $2\sigma$ .




Figure 5. Detail Sequence Alignment of Cry2Aa and Cry2Ab

Sequence alignment of the D and L block regions of Cry2Aa and Cry2Ab generated using ALSCRIPT [51]. In the alignment, identical amino acids are unmarked; similar residues (as defined by ALSCRIPT) are colored yellow, while dissimilar residues are marked green. The secondary structure associated with sequence is presented in the lowermost row. The block of secondary structure associated with D block residues is colored magenta, while that associated with L block residues is colored cyan.

regions of the protein sequence that confer differential specificity to Diptera and Lepidoptera [25] (Figure 4). In Figure 4, the first band represents the sequence of Cry2Aa with its high level of activity (+++) against both Lepidoptera and Diptera. The last band represents the Cry2Ab sequence that exhibits negligible activity (---) against Diptera and up to one order of magnitude lower activity against Lepidoptera when compared with Cry2Aa. The second band (DL112) represents a Cry2Aa chimera that contains the Cry2Ab sequence for the block D residues 307–340 (dipteran-specific). This chimera has negligible activity against Diptera and is suggested to have reduced activity (at the 1 $\sigma$  level) against Lepidoptera, indicating that block D correlates with dipteran specificity. The activity profile of a reverse chimera (the third band) [24], in which Cry2Ab contains the block

D sequence from Cry2Aa, shows a more significant reduction than DL112 against Lepidoptera (of a different species) but is only reduced 20-fold toward Diptera versus Cry2Aa. Thus antidipteran activity tracks with the D block of Cry2Aa.

The fourth band (DL115) represents a Cry2Aa chimera that contains the Cry2Ab sequence for the dipteran-disfavoring D block and for a neighboring region of sequence, the lepidopteran-disfavoring L block (residues 341–412). The activity profile of this construct against both Diptera and Lepidoptera most closely parallels that of Cry2Ab, which is consistent with blocks D and L encoding essentially all of the differential specificity determinants. In summary, the differential specificity for Diptera in Cry2Aa depends on block D, while that for Lepidoptera depends on block L. Maximal activity

Table 2. Solvent Accessible Surface Areas, Contacts within 3.4 Å, and Hydrogen Bonds for the Specificity-Confering Residues in Cry2Aa

Residue	Exposed Surface (Å <sup>2</sup> )	Exposed Surface Beyond C <sub>β</sub> (Å <sup>2</sup> )	Contacts
Dipteran Specificity-Confering			
Ile307	6	4	Ser309, Ser343, Gly481, (Met483), (Tyr342)
Ser309	26	26	Asn341, Ile307, Thr364, (Ser363)
Ile311	1	0	Cys362, (Arg339), (Asn361)
Thr314	7	7	Ser337, Asn357, Asn336, His358, (Asn359)
Ile318	91	89	Thr332, (Thr331)
Gly324	78	0	
Ser334	5	5	Leu316, Asn336, (Phe409), (Gln399), (Arg315)
Asn336	6	6	Thr314, Ser334, Ala460, Ala353, (Gly313), (Ile351)
Ser337	0	0	Thr314, Ala353, His358
Lepidopteran Specificity-Confering			
Val346	39	34	Tyr342, (Asn303), (Gly344)
Leu350	27	26	Asn449, Ile450
Thr354	50	26	Glu451
Asn355	109	76	(Pro457)
Leu356	60	43	(Ala353)
His358	43	14	Ser312, Thr314, Ser337, (Gly313)
Val365	107	75	(Asn336)
Ser370	68	39	Pro367, (His21)
Thr382	54	24	(Asn392), (Thr391)
Ser390	9	9	Ser329, Thr331, Asp383
Gln399	33	33	Val374, Arg375, Arg405, (Leu404)
Ser403	93	73	
Cys406	37	27	Ser397, Phe398, Cys362
Ser410	89	72	

All data were calculated for the activated toxin using HBPLUS [50]. Entries in the left-most column are the 23 specificity-conferring residues. Entries in the right-most column conform to hydrogen bonding geometry, except for those enclosed in parentheses that are van der Waals contacts. Bold entries in the right-most column identify specificity-conferring residues also found in the left-most column.




Figure 6. Restriction Maps Detailing the Construction of Plasmid pSB307

(a) Nucleotide sequences of the oligonucleotides GKP-6 and GKP-7.  
(b) Restriction maps of pSB302, pSB304, and pSB307.

against Lepidoptera, as seen in Cry2Aa, still requires some contribution from block D (sequence alignment presented in Figure 5).

Figure 2a projects the Cry2Aa/Cry2Ab homolog differences onto the van der Waals surface of Cry2Aa (for clarity, only domains II and III are shown). In the D block, there are nine residues that differ between Cry2Aa and Cry2Ab. Surprisingly, most of these are buried. The notable exceptions are Ile318 and Gly324 (Asn and Val, respectively, in Cry2Ab), which are distant from the putative binding epitope, and the moderately exposed Ser309 (Asn in Cry2Ab) within the putative binding epitope (Table 2). Ile307 and Ile311 are found packed behind exposed residues on the putative binding surface. Almost half of the variant residues from block D (Thr314, Ser334, Asn336, and Ser337) are in a cluster that is packed behind the  $\beta$ 4- $\beta$ 5 loop presented from within the 72-residue L block (Figures 2b and 2c).

Two of these buried variant residues, Thr314 and Ser337, make side chain-main chain hydrogen bonds with the  $\beta$ 4- $\beta$ 5 loop. A third residue, Asn336, makes main chain-main chain hydrogen bonds with the  $\beta$ 4- $\beta$ 5 loop, and Thr314 makes side chain-side chain hydrogen bonds with Ser334. In the less active homolog, Cry2Ab, these residues are replaced with approximately isosteric nonhydrogen bonding residues, suggesting that this pattern of substitutions abolishes affinity for the dipteran receptor (Thr314Ala, Ser334Ala, Asn336Leu, and Ser337Ala). It is conceivable that the Ile318Val and Gly324Val substitutions are part of a region of the protein that interacts only with the receptor(s) found in dipteran species and shares some components with the putative binding epitope that we identify. However, we speculate that the same exposed surface area binds to the lepidopteran and dipteran receptors. In this model, these solvent inaccessible residues behind the putative receptor binding surface may serve to alter the conformation of the  $\beta$ 4- $\beta$ 5 loop, with its several hydrophilic specificity-determining residues. Similar modulation of specificity in protein-protein interactions by noncontact residues is seen in the context of immunoglobulin residues that affect conformation of the complementarity-determining residues (CDR) at the binding surface [34]. Likewise, affinity maturation of a Fab/antigen complex results in the optimization of antibody/antigen binding by residues 15 Å from the interaction surface [35].

The structures of Bt toxins provide a template for design and discovery of changes that alter receptor targeting in order to either broaden selectivity for better field efficacy, prolong the life of existing agents, or avoid

unwanted effects on nontarget organisms. Resistance to Bt toxins is recognized as a potential limitation in their application. Early studies concluded that recessive genes controlled the inheritance of Bt resistance. However, a recent study suggests that Bt resistance can be inherited as an incompletely dominant autosomal gene [36]. The authors note that such a mechanism of Bt resistance inheritance in the field would significantly reduce the usefulness of the high dose/refuge strategy of resistance management in which some mates are not challenged with toxin. Knowledge of any presumed modifications in the receptor that cause resistance can potentially instruct rational protein engineering of the receptor binding surface to yield toxins that might bypass resistance and still bind to the modified receptor of resistant insect species.

Potential collateral effects upon nontarget insect species [36] and effects upon nontarget predatory insects that consume target insect species [37] have been attributed to Bt GM crops. The structures provide a blueprint for focused mutagenesis followed by screening to select for each specific target species in a particular crop, so as to diminish collateral toxicity to nontarget species. By shedding light on the molecular basis of toxin-host receptor recognition, the structure provides a foundation for engineering Bt-based toxin genes that may develop broader insect species specificity, species selectivity tuned to reduce collateral impact upon nontarget species, and longer field efficacy.

## Biological Implications

We have determined the three-dimensional structure of the insecticidal toxin Cry2Aa in order to understand the structural determinants of toxin specificity. Genetically modified (GM) crops that express insecticidal protein toxins are an integral part of modern agriculture. Proteins normally produced by different strains of *Bacillus thuringiensis* (Bt) during sporulation mediate a species-specific pathogenicity of Bt toward insect larvae of the target species and are the active agents in the majority of biorational pesticides and insect-resistant transgenic crops. Though promising as a crop protection alternative, problems exist with transgenic crops. Bt GM crops may pose a threat to nontarget insect species [16] or to nontarget predatory insects that consume target insect species [37]. In addition, resistance to Bt toxins is recognized as a potential limitation to their application that is ecologically friendlier than traditional organic pesticides. For instance, EPA approval of Bt GM maize was

contingent upon the establishment of viable resistance management strategies [36].

Cry2Aa is among an unusual subset of crystalline (Cry) proteins possessing broad insect species specificity by exhibiting high specific activity against larvae from two insect orders, Lepidoptera and Diptera [24, 25], of agricultural and public health significance. Also, the Cry2Aa protoxin is significantly smaller (72 kDa) than those of the Cry1 proteins (~135 kDa) in the current generation of transgenic crops. Since gene size can be a limiting factor of protein expression in plants, transgenic constructs based upon Cry1 usually express a smaller portion of the gene that contains essentially the activated toxin. Cry protoxins are presumed to be more environmentally stable than the activated toxins; hence, transgenic constructs that express the Cry2Aa protoxin could deliver higher toxin doses in the field due to greater stability [22]. Also, expression of the protoxin reduces collateral damage to nontarget insect species since it depends on specificity of the host proteases for activation [3, 37]. Chloroplast-directed overexpression of the Cry2Aa protoxin has been demonstrated and shows expression levels equivalent to 2%–3% total soluble protein in transformed leaves [22]. Such high levels of expression, 20- to 30-fold higher than current nuclear transgenics, could diminish the opportunity for developing resistance by significantly increasing toxin dose at the initial encounter with the insect.

Cry2Ab, an 87% sequence identical homolog of Cry2Aa, has negligible activity against dipteran species and 3- to 8-fold less activity against certain lepidopteran species [25, 26]. Also, there exists a unique body of chimeric-scanning mutagenesis data in the Cry2Aa/Cry2Ab system that has identified determinants of species specificity in the amino acid sequence [24, 25]. Correlating the structure with chimeric-scanning data indicates that the putative receptor binding epitope of Cry2Aa lies on the core  $\beta$  sheet and differs from the end of the  $\beta$  sheet apical loops of domain II, as suggested from structures of the other Cry toxins [28, 29]. Thus, a target surface is defined for directed mutagenesis that may focus engineering of the toxin either to develop broader insect species specificity, species selectivity tuned to reduce collateral impact upon nontarget species, or longer field efficacy. Until now, the search for new insecticidal bacterial toxins involved collection and assay of novel isolates of Bt and other bacteria known to have insecticidal activity. Recent reports describe the isolation of bacterial species that produce new classes of insecticidal toxin [38]. These structure data may permit rational engineering of insecticidal Cry toxins with desired characteristics.

## Experimental Procedures

### Cloning of Cry2Aa

Oligonucleotide primers flanking the coding region of *cry2Aa* were generated based on the published sequence of the gene from Bt *kurstaki* strain HD-1 [26]. Primer GKP-6 is a 29-mer that corresponds to the N-terminal 26 nucleotides of the coding region (Figure 6a). Primer GKP-7 is a 25-mer that corresponds to a fragment overlapping the HindIII site that is located ~350 nucleotides downstream from the stop codon (Figure 6a). Plasmid DNA isolated from Bt *kurstaki* HD-1 served as a template for the PCR reaction. The re-

sulting 2100 bp fragment was purified and served as the probe used to identify the Cry2Aa operon with its accompanying open reading frames. The hexamer-primed labeling method was used to incorporate  $^{32}$ P-dCTP into the probe.

Previously, it was indicated that the entire gene, including the coding region and the promoter, is present on a 5.0 kb HindIII fragment [26] of a plasmid isolated from Bt *kurstaki* HD-1. The 3.5–7 kb fragments obtained by HindIII digestion of plasmid DNA isolated from Bt *kurstaki* HD-1 were ligated into an *E. coli* cloning vector, pTZ18R (Pharmacia, vecbase accession #VB0071) and were used to transform *E. coli* DH5 cells by electroporation. Electroporated DH5 cells were plated onto LB-Amp<sup>50</sup> plates containing X-gal and IPTG for color selection. The presence of the *cry2Aa* gene in the transformed colonies (white) was confirmed by hybridization of the PCR-generated probe. Restriction analysis was used to confirm that the clones contained inserts with the *cry2Aa* gene and also to establish the orientation with which the fragment was inserted into pTZ18R. The results of this analysis revealed that one of the clones corresponded to the orientation designated pSB302 (Figure 6b), while two clones had the opposite orientation and were designated pSB303, pSB304, obtained by deleting the 1.2 kb-BamHI fragment (dotted line in Figure 6b), was also transformed into DH5.

Total protein analysis for proteins produced by *E. coli* strain DH5 carrying pSB302, pSB303, or pSB304 was performed by SDS-PAGE. A protein band of molecular weight 62 kDa, absent in the original DH5 cells, was observed in all of the clones examined. The level of expression was the highest in those cells bearing pSB304. Most of the toxin could be found in the pelletable fraction following sonication of the cells. Samples were evaluated for biological activity by bioassay using *Manduca sexta* as the target insect. All of the clones (pSB302, pSB303, and pSB304) were active with LD<sub>50</sub> values of ~500 ppm.

The pSB304 plasmid retains a unique EcoRI site, ~200 nucleotides upstream of the *cry2Aa* promoter, into which the EcoRI-linearized *Bacillus cereus* vector pBC16.1 (GenBank accession number U32369) was cloned (Figure 6b). The resulting clone was used to transform *E. coli* DH5, and clones containing the new plasmid were designated pSB307. Confirmation of the identity of the new plasmid and determination of the orientation of the pBC16.1 insert, with respect to the *cry2Aa* gene, was made by restriction mapping. One of the plasmids, pSB307.4, was transformed into Bt *cryB* (a *cry* strain) by electroporation. The plasmid content of these isolates was verified by restriction mapping.

Cry2Aa expressed well in Bt *cryB* cells transformed with pSB307.4, and the protein formed crystalline (rhombohedral) inclusions. The cells were harvested by centrifugation, washed with water, and lyophilized. Dried cell mass was added to the insect diet and fed to *M. sexta* larvae. The results confirmed that Bt *cryB* (pSB307.4) exhibited high insecticidal activity.

### Protein Expression and Purification

The plasmid (pSB307.4) containing the Cry2Aa operon, with its accompanying open reading frames, was used to transform the *cry* strain of Bt (*cryB*) as previously described [39]. Cry2Aa was purified from the crystalline inclusions produced in the cells. Inclusions were harvested by cell lysis and centrifugation. Crystalline inclusions were washed repeatedly with 0.5 N NaCl to remove proteases and were transferred to buffer (10 mM Tris-HCl, 1 mM EDTA [pH 8.0]) with 2% mercaptoethanol. Titrating the pH to 10.5, using NH<sub>4</sub>OH, solubilized the protein from the crystalline inclusion bodies. The protein was purified by Sephacryl S300HR column chromatography as described [40] and concentrated by ultrafiltration to 10 mg ml<sup>-1</sup>.

### Crystallization and Structure Determination

For recrystallization, hanging drops of the resulting concentrated protein (10  $\mu$ l concentrated protein buffered as described above) were equilibrated against wells that contained Tris buffer (10 mM Tris-HCl, 1 mM EDTA [pH 8.0]). Crystallization was induced by the gradual shift to neutral pH as the mobile NH<sub>3</sub> diffused from the drops. Crystals were transferred to storage buffer (50 mM PIPES, 250 mM NaCl [pH 6.8]) with 2% mercaptoethanol. The resulting crystals are in spacegroup P4<sub>3</sub>2<sub>1</sub>2; unit cell constants  $a = 85.6$  Å,  $c = 163.9$  Å. They have one monomer in the asymmetric unit, an

estimated 34% solvent content, and diffract to  $\sim 3.0$  Å using Cu K $\alpha$  X-rays from a rotating anode generator and to 2.0 Å at a synchrotron source after flash freezing.

For the collection of data at 100K, the crystals were transferred in three steps to a final 20% solution of cryo-protectant (a 1:1 mixture of 1,2-propane diol and glycerol) and storage buffer and flash frozen in a cold nitrogen stream. X-ray diffraction data were collected at SSRL beamline 7.1 using a wavelength of 1.08 Å. Intensity data were integrated, scaled, and merged using HKL [41]. The overall Wilson B factor ( $3.0$  Å  $< d < 2.2$  Å) was 14 Å<sup>2</sup>.

De novo phasing was achieved using multiple isomorphous replacement after attempts to find a molecular replacement solution to the phase problem employing the available coordinates of Cry3Aa and Cry1Aa were unsuccessful. The heavy atom derivatives (Table 1) were solved from difference Patterson maps as displayed using XtalView [42]. Difference Fourier inspection for minor sites and refinement of the heavy atom positions, occupancies, and B factors was completed in PHASES [43]. The resulting protein electron density map was subjected to solvent-flipping density modification, as implemented in Solomon [44]. The helical bundle was apparent in 5 Å maps; at 3 Å resolution, the correct enantiomorph was clear from its stereochemistry. Using Cry1Aa as the initial building template, polyalanine versions of the helical and jellyroll domains were manually positioned using O [45], and the fit was optimized using the real-space refinement package ESSENS [46]. Positional and simulated annealing refinement were carried out using the maximum likelihood target of XPLOR 3.85x [47].

#### Acknowledgments

We thank D.H. Dean, E.A. Zhukovsky, J. Finer-Moore, and R.J. Fletterick for helpful discussions during the course of this investigation. We thank V. Ramalingam for assistance in crystallization and data collection and G.K. Powell for providing us with the Cry2Aa clone. This work is based upon research conducted at SSRL, which is funded by the Department of Energy, Office of Basic Energy Sciences. This work was supported by the National Institutes of Health (GM-244485 to R.M.S.).

Received: December 27, 2000

Revised: April 4, 2001

Accepted: April 6, 2001

#### References

- Schnepf, E., et al., and Dean, D.H. (1998). *Bacillus thuringiensis* and its pesticidal crystal proteins. *Microbiol. Mol. Biol. Rev.* 62, 775–806.
- Tojo, A., and Aizawa, K. (1983). Dissolution and degradation of *Bacillus thuringiensis*  $\delta$ -endotoxin by gut juice protease of the silkworm *Bombyx mori*. *Appl. Environ. Microbiol.* 45, 576–580.
- Aronson, A.I., Han, E.S., McGaughey, W., and Johnson, D. (1991). The solubility of inclusion proteins from *Bacillus thuringiensis* is dependent upon protoxin composition and is a factor in toxicity to insects. *Appl. Environ. Microbiol.* 57, 981–986.
- Choma, T., Surewicz, W.R., Carey, P.R., Pozsgay, M., Raynor, T., and Kaplan, H. (1990). Unusual proteolysis of the protoxin and toxin from *Bacillus thuringiensis*. Structural implications. *Eur. J. Biochem.* 189, 523–527.
- Hofmann, C., Vanderbruggen, H., Höfte, H., Van Rie, J., Jansens, S., and Van Mellaert, H. (1988). Specificity of *Bacillus thuringiensis*  $\delta$ -endotoxins is correlated with the presence of high-affinity binding sites in the brush border membrane of target insect midguts. *Proc. Nat. Acad. Sci. USA* 85, 7844–7848.
- Wolfersberger, M.G., Hofmann, C., and Lüthy, P. (1986). Interaction of *Bacillus thuringiensis* with membrane vesicles isolated from lepidopteran larval midgut. *Zbl. Bakt. Mikrobiol. Hyg. I. Suppl.* 15, 237–238.
- Van Rie, J., Jansens, S., Höfte, H., Degheele, D., and Van Mellaert, H. (1989). Specificity of *Bacillus thuringiensis*  $\delta$ -endotoxins: importance of specific receptors on the brush border membrane of the mid-gut of target insects. *Eur. J. Biochem.* 186, 239–247.
- Slatin, S.L., Abrams, C.K., and English, L. (1990). Delta-endotoxins form cation-selective channels in planar lipid bilayers. *Biochem. Biophys. Res. Commun.* 169, 765–772.
- English, L., Readdy, T.L., and Bastian, A.E. (1991). Delta-endotoxin-induced leakage of  $^{86}\text{Rb}^+$ -K $^+$  and H $_2$ O from phospholipid vesicles is catalyzed by reconstituted midgut membrane. *Insect Biochem.* 21, 177–184.
- Schwartz, J.L., Gameau, L., Savaria, D., Masson, L., and Brousseau, R. (1993). Lepidopteran-specific crystal toxins from *Bacillus thuringiensis* form cation- and anion-selective channels in planar lipid bilayers. *J. Membrane Biol.* 132, 53–62.
- Harvey, W.R., and Wolfersberger, M.G. (1979). Mechanism of inhibition of active potassium transport in isolated midgut of *Manduca sexta* by *Bacillus thuringiensis* endotoxin. *J. Exp. Biol.* 83, 293–304.
- Harvey, W.R., Cioffi, M., and Wolfersberger, M.G. (1986). Transport physiology of lepidopteran midgut in relation to the action of *B.t.* delta-endotoxin. In *Fundamental and Applied Aspects of Invertebrate Pathology*, J.M. Vlak, D. Peters, and R.A. Samson, eds. (Wageningen, The Netherlands: Grafisch Bedrijf Ponsen and Looijen), pp. 11–14.
- Knowles, B.H., and Ellar, D.J. (1987). Colloid-osmotic lysis is a general feature of the mechanism of *Bacillus thuringiensis*  $\delta$ -endotoxins with different insect specificity. *Biochem. Biophys. Acta* 924, 509–518.
- Wolfersberger, M.G. (1992). V-ATPase energized epithelia and biological insect control. *J. Exp. Biol.* 172, 377–386.
- Crickmore, N., et al., and Dean, D.H. (1998). Revision of the nomenclature of the *Bacillus thuringiensis* pesticidal crystal proteins. *Microbiol. Mol. Biol. Rev.* 62, 807–813.
- Losey, J.E., Rayor, L.S., and Carter, M.E. (1999). Transgenic pollen harms monarch larvae. *Nature* 399, 214.
- Van Rie, J., McGaughey, W.H., Johnson, D.E., Barnett, B.D., and Van Mellaert, H. (1990). Mechanism of insect resistance to the microbial insecticide *Bacillus thuringiensis*. *Science* 247, 72–74.
- McGaughey, W.H., Gould, F., and Gelertner, W. (1998). Bt resistance management. *Nature Biotechnol.* 16, 144–146.
- Yamamoto, T., and McLaughlin, R.E. (1981). Isolation of a protein from the parasporal crystal of *Bacillus thuringiensis* var. *kurstaki* toxic to the mosquito larva *Aedes taeniorhynchus*. *Biochem. Biophys. Res. Commun.* 103, 414–421.
- Donovan, W.P., Dankocsik, C.C., Gilbert, M.P., Gawron-Burke, M.C., Groat, R.G., and Carlton, B.C. (1988). Amino acid sequence and entomocidal activity of the P2 crystal protein. An insect toxin from *Bacillus thuringiensis* var. *kurstaki*. *J. Biol. Chem.* 263, 561–567.
- Yamamoto, T., and Powell, G.K. (1993). *Bacillus thuringiensis* crystal proteins: recent advances in understanding its insecticidal activity. In *Advanced Engineered Pesticides*. L. Kim, ed. (New York: Marcel Dekker), pp. 3–42.
- Kota, M., Daniell, H., Varna, S., Garczynski, S.F., Gould, F., and Moar, W.J. (1999). Overexpression of the *Bacillus thuringiensis* (Bt) Cry2Aa2 protein in chloroplasts confers resistance to plants against susceptible and Bt-resistant insects. *Proc. Nat. Acad. Sci. USA* 96, 1840–1845.
- English, L., et al., and Slatin, S.L. (1994). Mode of action of CryIIA: a *Bacillus thuringiensis* delta-endotoxin. *Insect Biochem. Mol. Biol.* 24, 1025–1035.
- Widner, W.R., and Whiteley, H.R. (1990). Location of the dipteran specificity region in a lepidopteran-dipteran crystal protein from *Bacillus thuringiensis*. *J. Bact.* 172, 2826–2832.
- Liang, Y., and Dean, D.H. (1994). Location of a lepidopteran specificity region in insecticidal crystal protein CryIIA from *Bacillus thuringiensis*. *Mol. Microbiol.* 13, 569–575.
- Widner, W.R., and Whiteley, H.R. (1989). Two highly related insecticidal crystal proteins of *Bacillus thuringiensis* subsp. *kurstaki* possess different host range specificities. *J. Bacteriol.* 171, 965–974.
- Audtho, M., Valaitis, A.P., Alzate, O., and Dean, D.H. (1999). Production of chymotrypsin-resistant *Bacillus thuringiensis* Cry2Aa1 delta-endotoxin by protein engineering. *Appl. Environ. Microbiol.* 65, 4601–4605.
- Li, J., Carroll, J., and Ellar, D.J. (1991). Crystal structure of insect

- ticidal  $\delta$ -endotoxin from *Bacillus thuringiensis* at 2.5 Å resolution. *Nature* 353, 815–821.
29. Grochulski, P., et al, and Cygler, M. (1995). *Bacillus thuringiensis* CryIA(a) insecticidal toxin: crystal structure and channel formation. *J. Mol. Biol.* 254, 447–464.
30. Lee, M.K., Young, B.A., and Dean, D.H. (1995). Domain III exchanges of *Bacillus thuringiensis* Cry1A toxins affect binding to different gypsy moth midgut receptors. *Biochem. Biophys. Res. Commun.* 216, 306–312.
31. de Maagd, R.A., et al., and Bosch, D. (1996). Domain III substitution in *Bacillus thuringiensis* delta-endotoxin CryIA(b) results in superior toxicity for *Spodoptera exigua* and altered membrane protein recognition. *Appl. Environ. Microbiol.* 62, 1537–1543.
32. Schwartz, J.L., Potvin, L., Chen, X.J., Brousseau, R., Laprade, R., and Dean, D.H. (1997). Single-site mutations in the conserved alternating-arginine region affect ionic channels formed by CryIAa, a *Bacillus thuringiensis* toxin. *Appl. Environ. Microbiol.* 63, 3978–3984.
33. Von Tersch, M.A., Slatin, S.L., Kulesza, C.A., and English, L.H. (1994). Membrane-permeabilizing activities of *Bacillus thuringiensis* coleopteran-active toxin CryIIIB2 and CryIIIB2 domain I peptide. *Appl. Environ. Microbiol.* 60, 3711–3717.
34. Foote, J., and Winter, G. (1991). Antibody framework residues affecting the conformation of the hypervariable loops. *J. Mol. Biol.* 224, 487–499.
35. Wedemayer, G.J., Patten, P.A., Wang, L.H., Schultz, P.G., and Stevens, R.C. (1997). Structural insights into the evolution of an antibody combining site. *Science* 276, 1665–1669.
36. Huang, F., Buschman, L.L., Higgins, R.A., and McGaughey, W.H. (1999). Inheritance of resistance to *Bacillus thuringiensis* toxin (Dipel ES) in the European corn borer. *Science* 284, 965–967.
37. Hilbeck, A., Moar, W.J., Pusztai-Carey, M., Fillipini, A., and Bigler, F. (1999). Prey-mediated effects of Cry1Ab toxin and protoxin and Cry2A protoxin on the predator *Chrysoperla carnea*. *Entomol. Exp. Appl.* 91, 305–316.
38. Bowen D., et al., and French-Constant, R.H. (1998). Insecticidal toxins from the bacterium *Photorhabdus luminescens*. *Science* 280, 2129–2132.
39. Sasaki, J., et al., and Yamamoto, T. (1996). Insecticidal activity of the protein encoded by the cryV gene of *Bacillus thuringiensis* *kurstaki* INA-02. *Curr. Microbiol.* 32, 195–200.
40. Yamamoto, T. (1989). Identification of entomocidal toxins of *Bacillus thuringiensis* by high-performance liquid chromatography. *ACS Symposium Series*, 432, 46–60.
41. Otwinowski, Z., and Minor, W. (1997). Processing of X-ray diffraction data collected in oscillation mode. *Methods Enzymol.* 276, 307–326.
42. McRee, D. (1993). *Practical Protein Crystallography*. (San Diego, CA: Academic Press).
43. Furey, W., and Swaminathan, S. (1997). PHASES-95: A program package for the processing and analysis of diffraction data from macromolecules. In *Methods Enzymology* C. Carter and R. Sweet, eds. (Orlando FL: Academic Press), pp. 307–326.
44. Abrahams, J.P., and Leslie, A.G. (1996). Methods used in the structure determination of bovine mitochondrial F-1 ATPase. *Acta Crystallogr. D* 52, 30–42.
45. Jones, T.A., Zou, J.Y., Cowan, S.W., and Kjeldgaard, M. (1991). Improved methods for building protein models in electron density maps and the location of errors in these models. *Acta Crystallogr. A* 47, 110–119.
46. Kleywegt, G.J., and Jones, T.A. (1997). Template convolution to enhance or detect structural features in macromolecular electron-density maps. *Acta Crystallogr. D* 53, 179–185.
47. Brünger, A.T. (1993). *X-PLOR Version 3.1 a System for X-ray Crystallography and NMR*. (New Haven, CT: Yale University Press).
48. Ferrin, T.E., Huang, C.C., Jarvis, L.E., and Langridge, R. (1988). The MIDAS display system. *J. Mol. Graph.* 6, 13–27, 36–37.
49. Nicholls, A. (1992). *GRASP Manual*. (New York: Columbia University).
50. McDonald, I.K., and Thornton, J.M. (1994). Satisfying hydrogen bonding potential in proteins. *J. Mol. Biol.* 238, 777–793.
51. Barton, G.J. (1993). ALSCRIPT: A tool to format multiple sequence alignments. *Protein Eng.* 6, 37–40.

# Accession Numbers

The coordinates and structure factors for Cry2Aa have been deposited with the Protein Data Bank (accession code 1I5P).

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**